Fino C, Vestergaard M, Ingmer H, Pierrel F, Gerdes K, Harms A, PasT of *Escherichia coli* sustains antibiotic tolerance and aerobic respiration as a bacterial homolog of mitochondrial Coq10. MicrobiologyOpen. 2020;9:e1064 10.1002/mbo3.1064

Kenn Gerdes and Alexander Harms should be considered joint senior authors.

1. INTRODUCTION {#mbo31064-sec-0001}
===============

Bacterial persisters are cells that transiently display antibiotic tolerance due to a dormant physiology and constitute a subpopulation of cells within the overall bacterial population (Balaban et al., [2019](#mbo31064-bib-0008){ref-type="ref"}). This phenomenon has been linked to treatment failure of chronic and relapsing infections in different clinical settings (Fauvart, De Groote, & Michiels, [2011](#mbo31064-bib-0019){ref-type="ref"}; Harms, Maisonneuve, & Gerdes, [2016](#mbo31064-bib-0029){ref-type="ref"}; Lewis, [2010](#mbo31064-bib-0043){ref-type="ref"}). One common example is urinary tract infections (UTIs) that often relapse and are frequently caused by uropathogenic strains of *Escherichia coli* (UPEC) (Flores‐Mireles, Walker, Caparon, & Hultgren, [2015](#mbo31064-bib-0020){ref-type="ref"}). These bacteria are thought to persist during antibiotic treatment in rectal reservoirs and intracellular biofilms, and the survival of UPECs isolated from recurrent UTIs was shown to correlate with higher levels of persister cells detectable in the population (Anderson et al., [2003](#mbo31064-bib-0002){ref-type="ref"}; Blango & Mulvey, [2010](#mbo31064-bib-0011){ref-type="ref"}; Glover, Moreira, Sperandio, & Zimmern, [2014](#mbo31064-bib-0022){ref-type="ref"}; Goneau et al., [2014](#mbo31064-bib-0023){ref-type="ref"}).

Although persister cells are ubiquitous and their formation and evolution have been studied in multiple human pathogens (Michiels, Van den Bergh, Verstraeten, Fauvart, & Michiels, [2016](#mbo31064-bib-0051){ref-type="ref"}), the molecular mechanisms underlying their antibiotic tolerance have remained largely elusive. Mechanistic studies have been performed primarily in laboratory model strains like *E. coli* K‐12 where multiple different pathways of persister cell formation have been described (Harms et al., [2016](#mbo31064-bib-0029){ref-type="ref"}; Lewis, [2010](#mbo31064-bib-0043){ref-type="ref"}). Among these, the dormant physiology of persister cells has been linked repeatedly to the reversible activation of toxin--antitoxin (TA) systems in different strains of *E. coli* as well as closely related *Salmonella* Typhimurium (Dörr, Vulic, & Lewis, [2010](#mbo31064-bib-0018){ref-type="ref"}; Harms et al., [2016](#mbo31064-bib-0029){ref-type="ref"}; Helaine et al., [2014](#mbo31064-bib-0030){ref-type="ref"}; Norton & Mulvey, [2012](#mbo31064-bib-0057){ref-type="ref"}; Verstraeten et al., [2015](#mbo31064-bib-0076){ref-type="ref"}). TA systems are composed of a toxin protein that can inhibit key cellular processes and a cognate antitoxin that represses the toxin\'s activity until it is degraded in response to cellular signaling (Harms, Brodersen, Mitarai, & Gerdes, [2018](#mbo31064-bib-0027){ref-type="ref"}). They can therefore act as genetically controlled switches to reversibly shut down bacterial growth, and as such, it is generally intuitive that TA systems might be well suited to control persister cell formation, survival, and resuscitation (Ronneau & Helaine, [2019](#mbo31064-bib-0063){ref-type="ref"}). However, the relative importance of specific factors such as TA systems has remained controversial compared to global changes via modulation of the cellular core machinery including electron transport or ATP synthesis (Goneau et al., [2014](#mbo31064-bib-0023){ref-type="ref"}; Goormaghtigh et al., [2018](#mbo31064-bib-0024){ref-type="ref"}; Harms et al., [2016](#mbo31064-bib-0029){ref-type="ref"}; Pontes & Groisman, [2019](#mbo31064-bib-0060){ref-type="ref"}; Shan et al., [2017](#mbo31064-bib-0065){ref-type="ref"}). We previously discovered that a once well‐established link between ten particular TA systems of *E. coli* K‐12 and persister formation is wrong (Goormaghtigh et al., [2018](#mbo31064-bib-0024){ref-type="ref"}; Harms, Fino, Sørensen, Semsey, & Gerdes, [2017](#mbo31064-bib-0028){ref-type="ref"}), and the link between TA systems and persister formation in *Salmonella* Typhimurium has also recently been disputed (Pontes & Groisman, [2019](#mbo31064-bib-0060){ref-type="ref"}).

Given these debates, we became interested in a study that found the *pasTI* TA module of UPEC strain CFT073 to be critical for antibiotic‐tolerant persister cells (Norton & Mulvey, [2012](#mbo31064-bib-0057){ref-type="ref"}). Remarkably, the orthologous system in *E. coli* K‐12, *ratAB,* seemed to play no role in persister formation under the same conditions. However, the molecular basis of PasTI‐dependent drug tolerance in UPECs remained unclear. Previous work had proposed that the RatA toxin of *E. coli* K‐12 is a translation inhibitor that interferes with 70S ribosome assembly but did not experimentally confirm the role of RatB as the cognate antitoxin, questioning the notion that RatAB/PasTI is indeed a TA system (Zhang & Inouye, [2011](#mbo31064-bib-0083){ref-type="ref"}).

In this study, we therefore aimed at uncovering the molecular activity and biological function of PasTI/RatAB in *E. coli* to shed more light on the role of this TA system in persister formation and persister cells in clinical contexts. While we readily reproduced that PasT is critical for the formation or survival of ciprofloxacin‐tolerant cells by *E. coli* CFT073 and other pathogenic enterobacteria, we could not confirm that PasTI is a TA system. Instead, we show that PasT is the bacterial homolog of mitochondrial protein Coq10 that acts as an important accessory factor in the ubiquinone‐dependent electron transport chain (ETC). We find that *E. coli* mutants lacking *pasT* display the same pleiotropic phenotypes as yeast *coq10* mutants including decreased membrane potential, increased sensitivity to oxidative stress, and modestly decreased ubiquinone biosynthesis. Remarkably, these signs of defective respiration in *E. coli* can be complemented by ectopic expression of human *coq10*, suggesting that PasT and Coq10 are functionally equivalent. We therefore conclude that PasT is a previously unrecognized player in bacterial respiratory electron transport and likely affects antibiotic tolerance indirectly via its roles in redox balance and/or energy metabolism.

2. MATERIALS AND METHODS {#mbo31064-sec-0002}
========================

2.1. Bacterial handling and culturing {#mbo31064-sec-0003}
-------------------------------------

*Escherichia coli* was routinely cultured in LB or M9 liquid medium at 37°C in glass culture tubes or Erlenmeyer flasks with agitation at 160 rpm, usually in a water bath shaker for physiological experiments. LB agar plates were routinely used as a solid medium. Selection for plasmid maintenance was performed with ampicillin at 30 µg/ml (mini‐R1 origin of replication) or 100 µg/ml (other origins of replication), chloramphenicol at 25 µg/ml, and kanamycin at 25 µg/ml. P*lac* was induced with 1 mM of isopropyl β‐[d]{.smallcaps}‐1‐thiogalactopyranoside (IPTG), while P*araB* was induced with 0.2% w/v of [l]{.smallcaps}‐arabinose. Whenever appropriate, liquid and solid media were supplemented with 1% w/v [d]{.smallcaps}‐glucose to reduce basal expression of both P*lac* and P*araB* promoters through catabolite repression. Unless indicated differently, the complementation of bacterial mutants with *E. coli* genes was performed using low‐copy plasmids (pNDM220 derivatives) carrying these genes including their own promoter, so that no ectopic induction of the constructs was necessary. When enforced expression was required (e.g., for the experiments shown in Figure [1](#mbo31064-fig-0001){ref-type="fig"} and Figure [A6f](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}) or to test heterologous complementation with distant homologs (e.g., Figure [8](#mbo31064-fig-0008){ref-type="fig"}), isogenic plasmids encoding genes without their endogenous promoters were used and the bacteria were continuously cultured in the presence of 1 mM of IPTG in overnight cultures and throughout the experiment to induce expression from the P*lac* promoter of pNDM220 derivatives (see all plasmids listed in Table [A2](#mbo31064-tbl-0002){ref-type="table"} in Appendix [1](#mbo31064-app-0001){ref-type="app"}).

![PasT does not inhibit bacterial growth. Spot assay of *E. coli* CFT073 harboring isogenic plasmids with different copy number encoding either *pasT* or the well‐studied TA module toxin *doc* (as positive control) under the control of a P*lac* promoter on LB agar plates containing 1 mM isopropyl β‐[d]{.smallcaps}‐1‐thiogalactopyranoside (IPTG) and repressed on LB agar plates containing 1% w/v [d]{.smallcaps}‐glucose (see details in Materials and Methods). Similar results were obtained for *pasT* expression in *E. coli* CFT073 Δ*pasTI*, *E. coli* K‐12 MG1655, and *E. coli* K‐12 MG1655 Δ*ratAB* (Figure [A1a](#mbo31064-fig-0010){ref-type="fig"}/b in Appendix [2](#mbo31064-app-0002){ref-type="app"}). No growth inhibition was also observed for the expression of *pasI* (Figure [A1c](#mbo31064-fig-0010){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}).](MBO3-9-e1064-g001){#mbo31064-fig-0001}

Bacteria were grown anaerobically on LB agar plates incubated in a plastic jar (cat\# 1.16387.0001; Merck) with an anaerobic atmosphere generation bag (cat\# 68061; Sigma). The formation of an anaerobic atmosphere was confirmed using Anaerotest strips (cat\# 1.15112.0001; Merck). 1% w/v [d]{.smallcaps}‐glucose was added as a fermentable carbon source to LB agar plates incubated anaerobically.

2.2. Preparation of culture media {#mbo31064-sec-0004}
---------------------------------

Lysogeny broth (LB) was prepared by dissolving 1% w/v of tryptone (cat\# LP0042; Oxoid), 0.5% w/v of yeast extract (cat\# LP0021; Oxoid), and 1% w/v of sodium chloride (cat\# 27810.364; VWR Chemicals) in Milli‐Q H~2~O and sterilized by autoclaving. LB agar plates were prepared by supplementing LB medium with agar and 1.5% w/v before autoclaving. M9 medium was prepared according to the Cold Spring Harbor Protocols (M[9](#mbo31064-bib-0048){ref-type="ref"} minimal medium (standard), [2010](#mbo31064-bib-0048){ref-type="ref"}) with modifications in the form of 1× M9 salts (stock solution prepared from 5× M9 salts, see below) supplemented with 0.4% w/v Amicase (cat\# 1002372245; Sigma; from 10% w/v sterile‐filtered stock), 0.4% w/v [d]{.smallcaps}‐glucose (cat\# 101176K; VWR Chemicals; from 40% w/v autoclaved stock), 2 mM MgSO~4~ (cat\#. 25.165.292; VWR Chemicals), 1 µg/ml thiamine (cat\# T1270; Sigma), and 100 µM CaCl~2~ (cat\# C3306; Sigma). The 5× M9 salt solution was prepared by dissolving 25.6 g Na~2~HPO~4~ (cat\# S9390; Merck), 6 g KH~2~PO~4~ (cat\# P0662; Sigma), 1 g NaCl (cat\# 277810.364; VWR Chemicals), and 2 g NH~4~Cl (cat\# 5470.1; Roth) in 400 ml Milli‐Q H~2~O supplemented with 20 µl of a 10 mg/ml FeSO~4~ solution (cat\# F8048; Sigma). After confirming a pH of 7.4, the solution was sterile‐filtered and stored in the dark.

2.3. Strain construction {#mbo31064-sec-0005}
------------------------

*E. coli* K‐12 MG1655 Δ*ratAB* and *E. coli* CFT073 Δ*pasTI* mutants (with identifiers CF083 and CF069/CF378, respectively) were constructed as scarless deletions using two‐step recombineering with a double‐selectable cassette encoding chloramphenicol resistance and *sacB* (sucrose sensitivity) that was amplified from template plasmid pKO4 (Lee et al., [2001](#mbo31064-bib-0042){ref-type="ref"}). Recombineering functions were expressed from pWRG99 (Blank, Hensel, & Gerlach, [2011](#mbo31064-bib-0012){ref-type="ref"}). The first step of recombineering replaced the target gene with the double‐selectable cassette, and the second step removed the double‐selectable cassette via recombineering with a pair of annealed 80‐mer oligonucleotides composed of twice 40 bp homologies flanking the desired deletion (Blank et al., [2011](#mbo31064-bib-0012){ref-type="ref"}). The negative selection was performed on LB agar plates supplemented with 6% w/v sucrose (cat\# S0389; Sigma; from a 60% w/v sterile‐filtered stock solution). *E. coli* K‐12 MG1655 and *E. coli* CFT073 derivatives were routinely transformed with plasmids using TSS transformation (Chung, Niemela, & Miller, [1989](#mbo31064-bib-0014){ref-type="ref"}) and electroporation, respectively. Deletions of *pasTI* in *E. coli* strains O157:H7 EDL933 and 55989 as well as in *Salmonella enterica* subsp. *enterica* Typhimurium strain SR‐11 were constructed using recombineering functions expressed from pKM208 of Murphy and Campellone ([2003](#mbo31064-bib-0054){ref-type="ref"}). For *E. coli* EDL933 and *S. enterica* SR‐11, scarless deletions via the double‐selectable cassette of pWRG100 were achieved (see above). For *E. coli* 55989, the *pasTI* locus was first replaced with an FRT‐flanked gene cassette encoding kanamycin resistance. In the second step, gene cassettes were removed using Flp recombinase expressed from pCP20 in a way that only a short FRT scar remained. All bacterial strains used in this study are listed in Table [A1](#mbo31064-tbl-0001){ref-type="table"} (Appendix [1](#mbo31064-app-0001){ref-type="app"}), all plasmids are listed in Table [A2](#mbo31064-tbl-0002){ref-type="table"} (Appendix [1](#mbo31064-app-0001){ref-type="app"}), and all oligonucleotides are listed in Table [A3](#mbo31064-tbl-0003){ref-type="table"} (Appendix [1](#mbo31064-app-0001){ref-type="app"}).

2.4. Plasmid construction {#mbo31064-sec-0006}
-------------------------

Plasmids were constructed using standard techniques of restriction‐based molecular cloning. Briefly, a PCR‐amplified fragment and the vector backbone were each cut with appropriate FastDigest restriction enzymes (Thermo Scientific). After fragment purification and backbone dephosphorylation (using FastAP dephosphorylase; Thermo Scientific), the two components were ligated together using the T4 ligase (Thermo Scientific). Site‐directed mutagenesis of plasmids was performed by PCR with partially overlapping primers as described by Liu and Naismith ([2008](#mbo31064-bib-0044){ref-type="ref"}). Plasmid construction was always confirmed by DNA sequencing. A list of all plasmids used in this study as well as details of their construction are given in Table [A2](#mbo31064-tbl-0002){ref-type="table"} (Appendix [1](#mbo31064-app-0001){ref-type="app"}). The sequences of all oligonucleotides used in this study are listed in Table [A3](#mbo31064-tbl-0003){ref-type="table"} (Appendix [1](#mbo31064-app-0001){ref-type="app"}).

The open reading frames of *Caulobacter crescentus cc1736* and human *coq10A* (one of the two human *coq10* isoforms) were obtained from GenScript after codon optimization for heterologous expression in *E. coli*. For *coq10,* we cloned the C‐terminal portion homologous to *pasT*/*cc1736* without the N‐terminal mitochondrial signal peptide sequence at its 5′ end (see Figure [A4a](#mbo31064-fig-0013){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}).

2.5. Sequence analyses and in silico predictions {#mbo31064-sec-0007}
------------------------------------------------

For the protein alignment shown in Figure [A4a](#mbo31064-fig-0013){ref-type="fig"} of Appendix [2](#mbo31064-app-0002){ref-type="app"}, amino acid sequences of *E. coli* CFT073 PasT (UniProt accession Q8FEY4), *C. crescentus* CC1736 (UniProt accession Q9A7I7), Coq10 of *Schizosaccharomyces pombe* (UniProt accession Q9USM9), and *Saccharomyces cerevisiae* (UniProt accession Q08058), as well as human Coq10A (UniProt accession Q96MF6), were aligned using MAFFT (implemented in Geneious v10.1.3) and manually curated. For the synteny analysis of *pasTI* loci shown in Figure [3](#mbo31064-fig-0003){ref-type="fig"}, the presence of prophages at a known integration hotspot next to *ssrA* (see Mao et al. ([2009](#mbo31064-bib-0049){ref-type="ref"})) was detected with PHASTER (Arndt et al., [2016](#mbo31064-bib-0005){ref-type="ref"}) while the integration of other specific gene content was analyzed by manual sequence comparisons.

Phyre2 (<https://www.sbg.bio.ic.ac.uk/phyre2>; Kelley, Mezulis, Yates, Wass, & Sternberg, [2015](#mbo31064-bib-0037){ref-type="ref"}) was used for the prediction of the tertiary structure of PasT (Figure [A4b](#mbo31064-fig-0013){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). The prediction of potential functional partners in Figure [A4c](#mbo31064-fig-0013){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"} was obtained using STRING ([https://string‐db.org/](https://string-db.org/); Szklarczyk et al., [2018](#mbo31064-bib-0072){ref-type="ref"}).

2.6. Spot assays {#mbo31064-sec-0008}
----------------

For the detection of bacterial growth inhibition upon expression of different proteins, 1.5 ml of dense overnight cultures of *E. coli* harboring indicated plasmids was adjusted to have the same optical density at 600 nm (OD600), washed once, and then serially diluted in sterile phosphate‐buffered saline (PBS). Subsequently, 10 µl of the serial dilutions was spotted on LB agar plates containing indicated supplements that induce or repress protein expression. Different copy numbers of otherwise isogenic plasmid vectors were achieved by merely changing the origin of replication on the otherwise identical plasmid backbone. Based on pNDM220 (mini‐R1 origin, low‐copy; Gotfredsen & Gerdes, [1998](#mbo31064-bib-0025){ref-type="ref"}), we thus created pAH186_SC101 and pAH186_ColE1 with SC101 (medium‐copy) and ColE1 (high‐copy) origins, respectively (Jahn, Vorpahl, Hubschmann, Harms, & Muller, [2016](#mbo31064-bib-0035){ref-type="ref"}). We assume that *pasT/ratA* cloned in pNDM220 is expressed at physiologically relevant levels due to a low plasmid copy number that should drive expression similar to the native chromosomal loci. A recent proteomic study revealed that RatA(YfjG) and RatB(YfjF) are expressed, under conditions identical to our experimental conditions (M9 medium with glucose as sole carbon source), to levels of ca. 30 and 50 molecules per cell, respectively (Supplementary Table 9 in Schmidt et al. ([2015](#mbo31064-bib-0064){ref-type="ref"})).

The Doc and HipA TA system toxins are kinases that inhibit bacterial growth through phosphorylation and concomitant inactivation of elongation factor Tu (EF‐Tu) or glutamyl tRNA synthetase, respectively (Castro‐Roa et al., [2013](#mbo31064-bib-0013){ref-type="ref"}; Germain, Castro‐Roa, Zenkin, & Gerdes, [2013](#mbo31064-bib-0021){ref-type="ref"}). To compare the colony size between strains, 1.5 ml of dense overnight cultures was washed in 100 µl of phosphate‐buffered saline (PBS), serially diluted in PBS, and spotted (10 µl) on LB agar plates. When indicated, LB agar plates were supplemented with inducers and/or incubated under anaerobic conditions.

2.7. Determination of minimum inhibitory concentration (MIC) {#mbo31064-sec-0009}
------------------------------------------------------------

The MIC of antibiotics for different *E. coli* strains was determined by broth dilution assays. In short, serial 1.5‐fold dilutions of antibiotics in M9 medium with suitable supplements were inoculated with the different bacterial strains as indicated, sealed with a breathable film, and agitated at 37°C/160 rpm overnight. The MIC was determined as the lowest concentration of antibiotic that prevented bacterial growth as detected by visual inspection.

2.8. Antibiotic tolerance assays {#mbo31064-sec-0010}
--------------------------------

The dynamics of antibiotic tolerance throughout the growth phases of *E. coli* were studied by performing antibiotic killing assays with bacterial cultures that had grown for different times after inoculation from overnight culture into the fresh medium as described previously (Harms et al., [2017](#mbo31064-bib-0028){ref-type="ref"}). In more detail, overnight cultures were inoculated from single colonies into 3 ml of M9 medium and grown for ca. 16 hr in plastic culture tubes (cat\# 62.515.006; Sarstedt). Subcultures of 10 ml M9 medium in Erlenmeyer flasks were inoculated 1:100 from these overnight cultures and agitated in a water bath at 37°C/160 rpm. All viable colony‐forming units (cfu) and antibiotic‐tolerant cfu (see below) were determined for isogenic cultures that had grown for different times after subculturing (from 0 hr to 8 hr) and represented the spectrum of bacterial growth phases from lag phase over exponential growth into stationary phase (see, e.g., the curve of colony‐forming units (cfu) plotted over time in Figure [2a](#mbo31064-fig-0002){ref-type="fig"}). Antibiotic tolerance was assayed by treating 3 ml aliquots of culture in plastic tubes with lethal concentrations of ciprofloxacin (10 µg/ml), ampicillin (100 µg/ml), or colistin (6.6 µg/ml) for 5 hr at 37°C/160 rpm. In parallel, cfu counts of the same untreated cultures were determined by plating serial dilutions on LB agar plates. The MIC of ciprofloxacin for *E. coli* K‐12 MG1655 and CFT073 including all tested mutant derivatives was 0.00780 µg/ml, that is, the bacteria were treated with \>1,000× MIC to avoid secondary effects of prophage activation (Harms et al., [2017](#mbo31064-bib-0028){ref-type="ref"}). The MIC of colistin for *E. coli* K‐12 MG1655 and CFT073 including all tested mutant derivatives was 1.3 µg/ml, that is, the treatment was done with ca. 4× MIC. The MIC of ampicillin was found to be 8.88 µg/ml for the K‐12 strains and 33 µg/m for the CFT073 strains, meaning that treatment with 100 µg/ml ampicillin (following reference Norton & Mulvey, [2012](#mbo31064-bib-0057){ref-type="ref"}) represented 11× MIC and 3× MIC, respectively.

![PasT is important for the formation or survival of ciprofloxacin‐tolerant persisters. (a) Bacterial growth (colony‐forming units (cfu)/ml; top graph) and dynamics of ciprofloxacin‐tolerant cells (tolerant cfu/ml; top graph), as well as the fraction of tolerant cells at each data point (bottom graph), were determined for cultures of *E. coli* CFT073 and CFT073 Δ*pasTI* over time from inoculation over exponential growth into stationary phase. In short, bacteria were cultured for 1 hr, 2 hr, 3 hr, etc., and at each time point, we determined (1) total bacterial cfu/ml by direct plating and (2) drug‐tolerant cfu/ml by plating after 5 hr of treatment with 10 µg/ml ciprofloxacin (see Materials and Methods for details). (b) The same experiment as described in (a) was performed for cultures of *E. coli* K‐12 MG1655 and its Δ*ratAB* derivative. A similar drop of tolerance in *E. coli* CFT073 Δ*pasTI* (and the lack thereof in *E. coli* K‐12 MG1655 Δ*ratAB*) was also observed for treatment with the membrane‐targeting antibiotic colistin but not with the β‐lactam ampicillin (Figure [A2b](#mbo31064-fig-0011){ref-type="fig"}/c in Appendix [2](#mbo31064-app-0002){ref-type="app"}). Similar results as obtained with *E. coli* CFT073 and its Δ*pasTI* mutant in (a) were also obtained with different pathogenic *E. coli* strains and *Salmonella* Typhimurium (Figure [A3a](#mbo31064-fig-0012){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). (c) Fractions of tolerant cells for cultures of *E. coli* CFT073 Δ*pasTI* harboring complementation plasmids encoding *pasTI* or *ratAB* as well as wild‐type and Δ*pasTI* carrying the empty vector (ev) were determined as shown in (a). (d) The fraction of tolerant cells at 5 hr after inoculation was determined for cultures of *E. coli* CFT073 Δ*pasTI* harboring complementation plasmids encoding *pasT*, *ratA*, or *ratB*. Time--kill curves of all strains included in (a‐d) sampled at this time point showed biphasic killing, demonstrating that the differences in surviving cfu/ml reflect different levels of persister cells (Figure [A2a](#mbo31064-fig-0011){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). All data points in (a‐d) represent the mean of results from at least three independent experiments, and error bars indicate standard deviations](MBO3-9-e1064-g002){#mbo31064-fig-0002}

After antibiotic treatment, 1.5 ml of the samples was washed in 1 ml of PBS, concentrated in 100 µl of PBS, serially diluted in PBS, and spotted (10 µl) on LB agar plates. Agar plates were incubated at 37°C for at least 24 hr, and cfu counts per milliliter were determined from spots containing 10 to 100 bacterial colonies. The fraction of antibiotic‐tolerant cells was calculated as the ratio of the cfu counts per milliliter after and before antibiotic treatment. To verify that antibiotic‐tolerant cfu represented persister cells, we performed time--kill curves and confirmed biphasic kinetics of antibiotic killing (see, e.g., Figure [A2a](#mbo31064-fig-0011){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}).

2.9. Hydrogen peroxide sensitivity assay {#mbo31064-sec-0011}
----------------------------------------

The dynamics of hydrogen peroxide sensitivity throughout bacterial growth phases were assayed similarly to the antibiotic tolerance assay with the exception that bacteria were challenged with 10 mM of hydrogen peroxide (H~2~O~2~) (from 10 M stock; \#cat 31642; Sigma) for 30 min instead of antibiotic treatment. Furthermore, experiments were only performed with bacteria grown up to no later than late‐exponential phase (4 hr after inoculation 1:100 from overnight culture) because we consistently observed complete tolerance to H~2~O~2~ in the stationary phase for all bacterial strains. When indicated, the cultures were treated with 20 mM of the antioxidant ascorbate (vitamin C; from 1 M stock; cat\# A5960) for 20 min before the challenge with H~2~O~2~.

2.10. Assessment of membrane potential using DiOC~2~(3) {#mbo31064-sec-0012}
-------------------------------------------------------

The bacterial membrane potential was assessed using indicator dye 3,3′‐diethyloxacarbocyanine iodide (DiOC~2~(3)) as implemented in the *Bac*Light Bacterial Membrane Potential Kit (Invitrogen, Thermo Fischer Scientific) according to the manufacturer\'s recommendations. The DiOC~2~(3) dye shows green fluorescence in bacteria at low concentrations but becomes more concentrated in cells with larger membrane potential, causing it to aggregate and shift the fluorescence toward red emission.

Per strain and replicate, 2 μl cells from stationary‐phase cultures were inoculated into 2 ml of fresh LB medium in 14‐ml Falcon round‐bottom tubes (Corning) and grown to an OD~600~ of 0.2 at 37°C with shaking (180 rpm). 10 μl culture was transferred to 980 μl filtered phosphate‐buffered saline. To each cell solution, 10 μl of a 3 mM DiOC~2~(3) solution was added and cells were stained for 30 min at room temperature. The assay was verified by depolarizing the membrane with the protonophore carbonyl cyanide 3‐chlorophenylhydrazone (CCCP) at a final concentration of 5 μM. Data were recorded on a BD Biosciences Accuri C6 Flow Cytometer (Becton, Dickinson, and Company), with emission filters suitable for detecting red and green fluorescence. Settings on the flow cytometer were as follows: 25\'000 recorded events at an FSC threshold of 15.000 and medium flow rate. Gating of stained cell population and analysis of flow cytometry data were performed in CFlow® (BD Accuri). As an indicator of membrane potential, the ratio of red to green fluorescence intensity was calculated.

2.11. Quantification of ubiquinone biosynthesis and levels {#mbo31064-sec-0013}
----------------------------------------------------------

Levels of isoprenoid quinones were determined in cell extracts using HPLC‐ECD‐MS (electrochemical detection--mass spectrometry) as previously described (Hajj Chehade et al., [2019](#mbo31064-bib-0026){ref-type="ref"}; Loiseau et al., [2017](#mbo31064-bib-0047){ref-type="ref"}). The de novo synthesis of ubiquinone (UQ~8~) and its early biosynthetic intermediate octaprenyl‐phenol (OPP) was studied by supplementing bacterial cultures with their ^13^C‐labeled precursor 4‐hydroxybenzoic acid (4‐HB) and analyzing the accumulation of ^13^C label in the molecules of interest. An illustration of the UQ~8~ biosynthetic pathway in *E. coli* was included in Figure [5a](#mbo31064-fig-0005){ref-type="fig"} for clarity.

Bacterial subcultures in 10 ml of M9 medium in Erlenmeyer flasks were inoculated 1:100 from dense overnight cultures and agitated in a shaking water bath at 37°C/160 rpm to early log phase (2 hr of growth for wild‐type and Δ*pasTI*/Δ*ratAB* strains; ca. 10^8^ cfu/ml) or late log phase (4 hr of growth for wild‐type and Δ*pasTI*/Δ*ratAB* strains; ca. 10^9^ cfu/ml) and then supplemented with 10 µM ^13^C~7~‐4‐HB (cat\# 587869; Sigma) for an additional period of 30 min. Subsequently, cells were cooled on ice, harvested by centrifugation, and washed with 1 ml of cold PBS. The weight of each cell pellet was determined, a proportional amount of the UQ~10~ standard was added, and isoprenoid quinones were extracted and analyzed by HPLC‐ECD‐MS. Single‐ion monitoring detected the following molecules: ^13^C~6~‐OPP (M+NH~4~ ^+^), m/z 662.0--663.0, 5--10 min, scan time 0.2 s; UQ~8~ (M+H^+^), m/z 727.0--728.0, 6--10 min, scan time 0.2 s; ^13^C~6~‐UQ~8~ (M+H^+^), m/z 733.0--734.0, 6--10 min, scan time 0.3 s; and UQ~10~ (M+NH~4~ ^+^), m/z 880.2--881.2, 10--17 min, scan time 0.2 s. Peak areas were corrected for sample loss during extraction based on the recovery of the UQ~10~ internal standard (typically higher than 80%) and were then normalized to the cell\'s wet weight. The ECD signal of UQ~8~ was converted into picomoles based on a calibration curve obtained with commercial UQ~10~.

2.12. Quantification and statistical analysis {#mbo31064-sec-0014}
---------------------------------------------

Data sets were analyzed by calculating the mean and standard deviation of at least three biological replicates for each experiment. Detailed information for each experiment is provided in the figure legends.

3. RESULTS {#mbo31064-sec-0015}
==========

3.1. *pasTI* does not encode a toxin--antitoxin system {#mbo31064-sec-0016}
------------------------------------------------------

One previous study proposed that the *pasTI* locus encodes a new TA system composed of the PasT toxin and the PasI antitoxin (Norton & Mulvey, [2012](#mbo31064-bib-0057){ref-type="ref"}). However, we did not detect any growth inhibition of *E. coli* CFT073 when *pasT* was either expressed at physiologically relevant levels from a low‐copy‐number plasmid or overexpressed from isogenic plasmids replicating at higher copy numbers (Figure [1](#mbo31064-fig-0001){ref-type="fig"}). Deletion mutants lacking the chromosomally encoded *pasTI* locus, a possible source of experimental interference, also failed to show any inhibition of growth upon *pasT* overexpression (Figure [A1a](#mbo31064-fig-0010){ref-type="fig"}, Appendix [2](#mbo31064-app-0002){ref-type="app"}). Similarly, the expression of *pasT* failed to inhibit the growth of *E. coli* K‐12 MG1655 (Figure [A1b](#mbo31064-fig-0010){ref-type="fig"}, Appendix [2](#mbo31064-app-0002){ref-type="app"}). No growth inhibition was also observed upon expression of the proposed antitoxin *pasI* (Figure [A1c](#mbo31064-fig-0010){ref-type="fig"}, Appendix [2](#mbo31064-app-0002){ref-type="app"}). We therefore concluded that the *pasTI* locus is unlikely to encode a TA system.

3.2. Lack of pasT impairs antibiotic tolerance of *E. coli* CFT073 {#mbo31064-sec-0017}
------------------------------------------------------------------

To gain deeper insight into the role of *pasTI* in *E. coli* persister formation, we monitored the level of antibiotic‐tolerant cells throughout the different bacterial growth phases as previously described (Harms et al., [2017](#mbo31064-bib-0028){ref-type="ref"}). Interestingly, we observed decreased survival of the *E. coli* CFT073 Δ*pasTI* mutant when treated with ciprofloxacin compared to the wild‐type during exponential growth and over into the stationary phase. This defect in survival was caused by a lower level of persister cells in the Δ*pasTI* mutant population (Figure [2a](#mbo31064-fig-0002){ref-type="fig"}; see also Figure [A2a](#mbo31064-fig-0011){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}), and similar results were obtained for treatment with the membrane‐targeting antibiotic colistin (Figure [A2b](#mbo31064-fig-0011){ref-type="fig"},d,f in Appendix [2](#mbo31064-app-0002){ref-type="app"}). For the β‐lactam ampicillin, we observed increased levels of tolerant cells for the Δ*pasTI* mutant, possibly caused by its partial growth defect since this class of antibiotics only kills actively growing cells (Figure [A2c,e](#mbo31064-fig-0011){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). Conversely, no phenotype was observed at any time of the growth curve when comparing antibiotic tolerance of *E. coli* K‐12 MG1655 and its Δ*ratAB* derivative (Figure [2b](#mbo31064-fig-0002){ref-type="fig"}; see also Figure [A2a](#mbo31064-fig-0011){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}).

These results were overall consistent with the previous observation that *pasTI* is somehow critical for the formation or survival of antibiotic‐tolerant persister cells in *E. coli* CFT073 but that *ratAB* in *E. coli* K‐12 MG1655 is not (Norton & Mulvey, [2012](#mbo31064-bib-0057){ref-type="ref"}). Both the *pasTI* and *ratAB* loci, provided *in trans* from a low‐copy plasmid, as well as *pasT* or *ratA* alone, could complement the phenotype of decreased ciprofloxacin persister levels of *E. coli* CFT073 Δ*pasTI* (Figure [2c,d](#mbo31064-fig-0002){ref-type="fig"}; see also Figure [A2a](#mbo31064-fig-0011){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). These results demonstrate that the defect of *E. coli* CFT073 Δ*pasTI* in persister formation or survival is linked to the lack of PasT. Furthermore, they reveal that the differential effect of a *pasTI*/*ratAB* knockout in the two *E. coli* strains is not due to differences between PasT and its ortholog RatA. This finding is not unexpected given the near identity of PasT and RatA protein sequences with two amino acid differences only (S90 and D111 in PasT of *E. coli* CFT073, and N90 and E111 in *E. coli* K‐12 MG1655). To clarify whether *E. coli* CFT073 or K‐12 is representative of enterobacteria in general, we tested the ciprofloxacin tolerance phenotype of *pasTI* mutants constructed in two additional pathogenic *E. coli* strains and the more distantly related *Salmonella* Typhimurium (Figure [A3](#mbo31064-fig-0012){ref-type="fig"}, Appendix [2](#mbo31064-app-0002){ref-type="app"}). Clearly, *pasTI* knockouts of *E. coli* O157:H7 strain EDL933 and *S. enterica* Typhimurium SR‐11 showed decreased levels of ciprofloxacin‐tolerant persisters that could be complemented by expression of *E. coli* CFT073 *pasT*. The other tested pathogenic *E. coli* strain 55989 also showed lower ciprofloxacin tolerance after *pasTI* was knocked out, but we cannot exclude that this phenotype might be partially caused by decreased intrinsic ciprofloxacin resistance of the *pasTI* mutant in this strain (Figure [A3](#mbo31064-fig-0012){ref-type="fig"}, Appendix [2](#mbo31064-app-0002){ref-type="app"}). Taken together, these results suggest that the phenotypes of *E. coli* CFT073 Δ*pasTI* and not of *E. coli* K‐12 Δ*ratAB* are more broadly representative.

3.3. *E. coli* PasT/RatA is the homolog of mitochondrial Coq10 {#mbo31064-sec-0018}
--------------------------------------------------------------

The *pasT*/*ratA* gene is well conserved among Proteobacteria and not always associated with *pasI*/*ratB* orthologs (Figure [3](#mbo31064-fig-0003){ref-type="fig"}), suggesting that PasT/RatA might have a conserved housekeeping function that can be exerted independently of its previously proposed antitoxin partner.

![*pasT* and, to a lesser extent, *pasI* are widely conserved among Proteobacteria. The genomic organization of *pasT* (green)/*pasI* (orange) loci is shown for representative Proteobacteria. Genes conserved in two or more organisms are shown in blue. A list of full strain names and genome accessions used for this synteny analysis is found in Table [A4](#mbo31064-tbl-0004){ref-type="table"} (Appendix [1](#mbo31064-app-0001){ref-type="app"}).](MBO3-9-e1064-g003){#mbo31064-fig-0003}

Interestingly, PasT shares a protein domain (Pfam: Polyketide_cyc2, PF10604; InterPro: StART domain, IPR005031) and modest sequence similarity to the mitochondrial protein Coq10 (Figure [A4a](#mbo31064-fig-0013){ref-type="fig"}/b, Appendix [2](#mbo31064-app-0002){ref-type="app"}; Shen et al., [2005](#mbo31064-bib-0068){ref-type="ref"}; Tsui et al., [2019](#mbo31064-bib-0074){ref-type="ref"}). Coq10 has been studied as an accessory factor of the mitochondrial electron transport chain (ETC), a series of protein complexes that create an electrochemical gradient across a membrane (the "proton‐motive force") which fuels cellular ATP synthesis (Figure [4a](#mbo31064-fig-0004){ref-type="fig"}; Anraku, [1988](#mbo31064-bib-0004){ref-type="ref"}). In *E. coli*, electron transport along the ETC involves the electron shuttle ubiquinone under aerobic conditions (Sharma, Teixeira de Mattos, Hellingwerf, & Bekker, [2012](#mbo31064-bib-0067){ref-type="ref"}) while two related but distinct molecules, menaquinone and demethylmenaquinone, predominate under anaerobic conditions (Nitzschke & Bettenbrock, [2018](#mbo31064-bib-0056){ref-type="ref"} and literature cited therein). Studies on yeast Coq10 indicated that this protein might serve as a "lipid chaperone" carrying newly synthesized ubiquinone to the respiratory complexes and/or localizing it properly within the ETC using a steroidogenic acute regulatory protein‐related lipid transfer (StART) domain (Figure [4a](#mbo31064-fig-0004){ref-type="fig"}; Awad et al., [2018](#mbo31064-bib-0007){ref-type="ref"}; Tran & Clarke, [2007](#mbo31064-bib-0073){ref-type="ref"}). Based on the similarity of the two proteins, we hypothesized that PasT/RatA might be the bacterial homolog of mitochondrial Coq10 and have a related or even equivalent role in cellular respiration.

![*E. coli* CFT073 Δ*pasTI* and *E. coli* MG1655 Δ*ratAB* mutants have a defective electron transport chain (ETC). (a) The figure illustrates how electrons (e^−^) flow in the mitochondrial electron transport chain (ETC) from complex I (NADH dehydrogenase) or complex II (succinate dehydrogenase) to complex III (cytochrome *bc* ~1~ complex) via membrane‐bound ubiquinone (commonly abbreviated as Q). Then, electrons transit via cytochrome C molecules and reach complex IV (cytochrome c oxidase) where they reduce dioxygen into water. Electron transfer is coupled to the active export of protons through the ETC complexes. The overall setup of this ETC is related in mitochondria and *E. coli*, but *E. coli* can also respire anaerobically by using alternative terminal electron acceptors and the dedicated anaerobic electron carriers menaquinone and demethylmenaquinone instead of ubiquinone. Studies on the mitochondrial ETC in yeast suggested that Coq10 is a "lipid chaperone" involved in the delivery of ubiquinone (synthesized by the multi‐subunit protein complex Q) to its sites of function and/or proper localization at the sites of function (recently reviewed by Awad et al., [2018](#mbo31064-bib-0007){ref-type="ref"}; Stefely & Pagliarini, [2017](#mbo31064-bib-0071){ref-type="ref"}; Tran & Clarke, [2007](#mbo31064-bib-0073){ref-type="ref"}). (b) The membrane potential of different *E. coli* samples was assessed using the DiOC~2~(3) dye in a way that a decrease in red/green ratio is indicative of depolarization (see Materials and Methods). Results were compared to values obtained with the uncoupler CCCP (complete depolarization) and the *E. coli* K‐12 *ubiA* mutant (unable to synthesize ubiquinone; Pelosi et al., [2019](#mbo31064-bib-0059){ref-type="ref"}). Both *ratAB* and---more pronounced---*pasTI* knockouts showed a decrease in the signal that was less strong than the effect of a *ubiA* knockout and could be complemented by *ratA*/*pasT*. (c, d) Minimum inhibitory concentrations (MIC) of *E. coli* CFT073 Δ*pasTI* for gentamicin (c) and zeocin (d) were determined by broth dilution assays. The bacteria carried either an empty vector (ev) or complementation plasmids encoding *pasTI*, *ratAB*, *pasT*, *ratA*, or *ratB*. For gentamicin, the result of one representative experiment is shown (additional independent replicates in Figure [A5a](#mbo31064-fig-0014){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). Similar results were obtained for *E. coli* K‐12 MG1655 Δ*ratAB*. (Figure [A5b](#mbo31064-fig-0014){ref-type="fig"}/c in Appendix [2](#mbo31064-app-0002){ref-type="app"}). Unless specified otherwise, data points represent the mean of results from three independent experiments, and error bars indicate standard deviations.](MBO3-9-e1064-g004){#mbo31064-fig-0004}

3.4. *E. coli ΔpasTI*/*ΔratAB* mutants display defective respiration and modest phenotypes in ubiquinone biosynthesis {#mbo31064-sec-0019}
---------------------------------------------------------------------------------------------------------------------

Yeast mutants lacking *coq10* are known to display defective electron transport (Allan et al., [2013](#mbo31064-bib-0001){ref-type="ref"}; Cui & Kawamukai, [2009](#mbo31064-bib-0015){ref-type="ref"}), and we therefore studied whether ETC functionality is also compromised in *E. coli* mutants lacking PasT/RatA. The efficiency of bacterial electron transport was assessed using fluorescent indicator dye DiOC~2~(3) to probe the cellular membrane potential. Compared to the parental wild‐type strains, both *pasTI* and *ratAB* mutants revealed a modest shift of signal toward the depolarized controls that could be complemented by providing *pasT* or *ratA in trans* (Figure [4b](#mbo31064-fig-0004){ref-type="fig"}). As an independent approach to study the same phenomenon, we compared the minimum inhibitory concentrations (MICs) of gentamicin and zeocin for growth of the *E. coli pasTI* and *ratAB* mutants and their parental wild‐type strains (Figure [4c,d](#mbo31064-fig-0004){ref-type="fig"}; see also Figure [A5a‐c](#mbo31064-fig-0014){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). The uptake of gentamicin and zeocin, antibiotics of the aminoglycoside and the bleomycin families, is directly dependent on and proportional to the proton‐motive force, so that impaired functionality of the ETC results in an increased MIC of these antibiotics (Krause, Serio, Kane, & Connolly, [2016](#mbo31064-bib-0041){ref-type="ref"}; Miller, Edberg, Mandel, Behar, & Steigbigel, [1980](#mbo31064-bib-0052){ref-type="ref"}; Søballe & Poole, [2000](#mbo31064-bib-0070){ref-type="ref"}). We indeed observed elevated MICs of both drugs for the *pasTI* and *ratAB* mutants that could be complemented with *pasT* or *ratA* but not *ratB* (Figure [4c,d](#mbo31064-fig-0004){ref-type="fig"}; see also Figure [A5a‐c](#mbo31064-fig-0014){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). Taken together, these results suggest a clear but modest decrease in membrane polarization as a consequence of defective electron transport for both *E. coli* CFT073 Δ*pasTI* and *E. coli* K‐12 MG1655 Δ*ratAB* mutants. Similar results were obtained with wild‐type and Δ*pasTI* variants of different pathogenic *E. coli*/*S. enterica* strains (Figure [A5d](#mbo31064-fig-0014){ref-type="fig"}/e in Appendix [2](#mbo31064-app-0002){ref-type="app"}).

To study the role of ubiquinone in these phenotypes, we quantified the total levels of ubiquinone and biosynthetic intermediates as well as the de novo biosynthesis of ubiquinone in *E. coli* Δ*pasTI*/Δ*ratAB* mutants (Figure [5a‐d](#mbo31064-fig-0005){ref-type="fig"}). Previous work found that yeast *coq10* mutants show decreased efficiency of ubiquinone biosynthesis specifically in exponential growth but have largely normal overall levels of ubiquinone in their mitochondria (Allan et al., [2013](#mbo31064-bib-0001){ref-type="ref"}; Barros et al., [2005](#mbo31064-bib-0009){ref-type="ref"}). Similarly, we saw no differences in total ubiquinone content when comparing *E. coli* Δ*pasTI*/Δ*ratAB* mutants to their parental wild‐type strains (Figure [5b](#mbo31064-fig-0005){ref-type="fig"}). However, we indeed found a decrease in ubiquinone precursor levels for both Δ*pasTI* and Δ*ratAB* mutants during the exponential growth phase and a mild defect in the de novo biosynthesis of ubiquinone specifically for CFT073 Δ*pasTI* in early log phase that could be complemented by *pasT*/*ratA* (Figure [5c](#mbo31064-fig-0005){ref-type="fig"}/d).

![Direct measurements of ubiquinone levels and biosynthesis. (a) Schematic summary of the ubiquinone (UQ~8~) biosynthetic pathway in *E. coli*. The precursor of 4‐hydroxybenzoic acid (4‐HB) is prenylated by UbiA and decarboxylated by UbiD to form the early intermediate octaprenyl‐phenol (OPP). Subsequent modifications of the aromatic ring by Ubi enzymes (UbiI, UbiG, UbiH, UbiE, and UbiF) yield ubiquinone 8 (UQ~8~). When ^13^C~7~‐4‐HB is added to cultures to evaluate de novo synthesis of UQ, ^13^C~6~‐OPP and ^13^C~6~‐UQ~8~ are formed (^13^C carbon atoms represented in green). (b) Total ubiquinone (UQ~8~) content (sum of ^13^C~6~‐UQ~8~ and unlabeled ubiquinone UQ~8~) was assessed after HPLC‐ECD‐MS analysis (see Materials and Methods) for early and late log‐phase cultures of *E. coli* CFT073, K‐12 MG1655, their Δ*pasTI*/Δ*ratAB* mutant derivatives, and the complemented strains. (c) The content of ^13^C~6~‐OPP (octaprenyl‐phenol, an early intermediate of the UQ~8~ pathway, see (a)) is reported for the same strains. (d) The plot shows the fraction of ^13^C~6~‐UQ~8~ over total UQ~8~ and is thus informative about the de novo biosynthesis of UQ~8~ for the same strains as in (b) and (c). All data points represent the mean of results from four independent experiments, and error bars indicate standard deviations. An *E. coli* K‐12 MG1655 *ubiX* mutant was used as a negative control in these experiments since UbiX is required for ubiquinone biosynthesis by producing a crucial cofactor for UbiD (Aussel et al., [2014](#mbo31064-bib-0006){ref-type="ref"}; White et al., [2015](#mbo31064-bib-0078){ref-type="ref"}; see also in (a)). ev = empty vector pNDM220, n.d. = not detected](MBO3-9-e1064-g005){#mbo31064-fig-0005}

3.5. *E. coli ΔpasTI*/*ΔratAB* mutants display increased susceptibility to oxidative stress {#mbo31064-sec-0020}
-------------------------------------------------------------------------------------------

Beyond defects in electron transport and log‐phase ubiquinone biosynthesis, yeast mutants lacking Coq10 are known to be hypersensitive to oxidative stress (Allan et al., [2013](#mbo31064-bib-0001){ref-type="ref"}; Cui & Kawamukai, [2009](#mbo31064-bib-0015){ref-type="ref"}). This phenomenon is consistent with our observation that *E. coli* and *Salmonella pasTI* and *ratAB* mutants grow like their parental wild‐types in the absence of oxygen but show a small‐colony phenotype under aerobic conditions (Figure [6a](#mbo31064-fig-0006){ref-type="fig"}; see also Figure [A6a‐b](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). Similar phenotypes are typical for bacterial mutants with defects in respiration and/or ubiquinone biosynthesis and have also been described for the *pasT* knockout of *E. coli* CFT073 in previous work (Aussel et al., [2014](#mbo31064-bib-0006){ref-type="ref"}; Day, [2013](#mbo31064-bib-0016){ref-type="ref"}; Koskiniemi, Pranting, Gullberg, Näsvall, & Andersson, [2011](#mbo31064-bib-0040){ref-type="ref"}; Norton & Mulvey, [2012](#mbo31064-bib-0057){ref-type="ref"}; Poon et al., [2000](#mbo31064-bib-0061){ref-type="ref"}; Proctor et al., [2014](#mbo31064-bib-0062){ref-type="ref"}; Xia et al., [2017](#mbo31064-bib-0079){ref-type="ref"}). Complementation with *pasT* or *ratA,* but not *ratB*, provided on a low‐copy plasmid enabled the growth of *E. coli pasTI* and *ratAB* mutants to normal colony size under aerobic conditions (Figure [6b,c](#mbo31064-fig-0006){ref-type="fig"}; see Figure [A6a](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}).

![Lack of *pasT*/*ratA* causes a small‐colony phenotype under aerobic conditions. (a) Cultures of *E. coli* CFT073 wild‐type, *E. coli* K‐12 MG1655 wild‐type, and their Δ*pasTI*/Δ*ratAB* derivatives were diluted and spotted on LB agar plates incubated either in the presence (left) or absence (right) of oxygen. [d]{.smallcaps}‐glucose (1% w/v) was added as a fermentable carbon source to LB agar plates incubated anaerobically (see Materials and Methods). (b, c) Spot assay of *E. coli* CFT073 Δ*pasTI* (b) or *E. coli* K‐12 MG1655 Δ*ratAB* (c) carrying the empty vector (ev) or different complementation plasmids was spotted on LB agar plates to visualize differences in colony size. Similar results as shown in (a‐c) were also obtained with different pathogenic *E. coli* strains and *Salmonella* Typhimurium (Figure [A6a](#mbo31064-fig-0015){ref-type="fig"}/b in Appendix [2](#mbo31064-app-0002){ref-type="app"})](MBO3-9-e1064-g006){#mbo31064-fig-0006}

We further compared the sensitivity of *E. coli* CFT073 Δ*pasTI* and its parental wild‐type to hydrogen peroxide (H~2~O~2~) as an exogenous source of oxidative damage (Figure [7a](#mbo31064-fig-0007){ref-type="fig"}). Similar to previous observations with yeast *coq10* mutants (Cui & Kawamukai, [2009](#mbo31064-bib-0015){ref-type="ref"}), the *pasT* knockout was hypersensitive to oxidative damage which could be abolished by pretreating the cultures with the potent antioxidant ascorbic acid (vitamin C; Figure [7b](#mbo31064-fig-0007){ref-type="fig"} and Figure [A6c‐e](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). The H~2~O~2~ sensitivity of *E. coli* CFT073 Δ*pasTI* could also be complemented *in trans* by *pasT/ratA,* but not *ratB*, expressed from their promoter (Figure [7c](#mbo31064-fig-0007){ref-type="fig"}). Taken together, these results presented in Figures [4](#mbo31064-fig-0004){ref-type="fig"}, [5](#mbo31064-fig-0005){ref-type="fig"}, [6](#mbo31064-fig-0006){ref-type="fig"}, [7](#mbo31064-fig-0007){ref-type="fig"} establish that the lack of PasT or RatA in *E. coli* causes similar phenotypes as known for yeast *coq10* mutants.

![*pasT*/*ratA* deficiency causes hypersensitivity to redox stress and oxidative damage in *E. coli*. (a) Dynamics of colony‐forming units (cfu/ml: top graph; a fraction of survivors: bottom graph) before and after treatment with hydrogen peroxide (H~2~O~2~) for *E. coli* CFT073 wild‐type/Δ*pasTI* over time after inoculation from stationary phase into fresh medium (see Materials and Methods). (b) The fraction of cells surviving H~2~O~2~ treatment 2 hr after inoculation from the stationary phase was determined for cultures of *E. coli* CFT073 wild‐type/Δ*pasTI* with or without pretreatment with the antioxidant vitamin C (ascorbate). Similar results as shown in (a) and (b) for *E. coli* CFT073 wild‐type/Δ*pasTI* were also obtained for *E. coli* K‐12 MG1655 wild‐type/Δ*ratAB* (Figure [A6d](#mbo31064-fig-0015){ref-type="fig"}/e in Appendix [2](#mbo31064-app-0002){ref-type="app"}). (c) The fraction of cells surviving H~2~O~2~ treatment 2 hr after inoculation from stationary phase was determined for cultures of *E. coli* CFT073 wild‐type/Δ*pasTI* carrying either the empty vector (ev) or different complementation plasmids. We could not assay the complementation of H~2~O~2~ sensitivity for *E. coli* K‐12 MG1655 Δ*ratAB* because, curiously, already the empty vector caused a strong decrease in H~2~O~2~ sensitivity of this strain (Figure [A6d](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). All data points in (a‐c) represent the mean of results from at least three independent experiments, and error bars indicate standard deviations](MBO3-9-e1064-g007){#mbo31064-fig-0007}

3.6. PasT deficiency in *E. coli* can be functionally complemented with human mitochondrial Coq10 {#mbo31064-sec-0021}
-------------------------------------------------------------------------------------------------

Given the high conservation of respiratory electron transport including the electron shuttle ubiquinone, we wondered whether PasT/RatA knockout phenotypes could be heterologously complemented by other bacterial or even mitochondrial homologs. Previous work had already shown that the alphaproteobacterial PasT homolog CC1376 of *C. crescentus* and human Coq10 can complement the *S. cerevisiae* Δ*coq10* phenotypes (Allan et al., [2013](#mbo31064-bib-0001){ref-type="ref"}; Barros et al., [2005](#mbo31064-bib-0009){ref-type="ref"}; Cui & Kawamukai, [2009](#mbo31064-bib-0015){ref-type="ref"}). Remarkably, both CC1376 and human mitochondrial Coq10 could also complement all phenotypes of RatA/PasT knockout mutants in *E. coli*: small colony size under aerobic condition, increased MIC of gentamicin/zeocin, defect of *E. coli* CFT073 in antibiotic tolerance, and, at least to some extent, H~2~O~2~ sensitivity (Figure [8a‐d](#mbo31064-fig-0008){ref-type="fig"} and Figure [A6f](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). These results show that RatA/PasT and CC1376 or Coq10 are not merely homologs (Figure [A4a](#mbo31064-fig-0013){ref-type="fig"}/b in Appendix [2](#mbo31064-app-0002){ref-type="app"}) but seem to also share a function linked to respiratory electron transport that is conserved from bacteria to humans.

![CC1736 of *Caulobacter crescentus* and human mitochondrial Coq10 can functionally complement the *E. coli* CFT073 Δ*pasTI* mutant. (a) The colony sizes of *E. coli* CFT073 strain harboring the empty vector (ev) or complementation plasmids encoding *pasT* homolog *cc1736* from *C. crescentus* or human *coq10* under P*lac* control were analyzed on LB agar plates supplemented with 1% [d]{.smallcaps}‐glucose (repressing expression of complementation constructs) or 1 mM IPTG (inducing expression of complementation plasmids). Similar results were obtained with *E. coli* K‐12 MG1655 Δ*ratAB* (Figure [A6f](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). (b) Minimum inhibitory concentration (MIC) of these strains for gentamicin (top) and zeocin (bottom) was determined via broth dilution assays. For gentamicin, results of one representative experiment are presented; additional independent replicates and similar data obtained with *E. coli* K‐12 MG1655 Δ*ratAB* are shown in Appendix [2](#mbo31064-app-0002){ref-type="app"} (Figure [A5a‐c](#mbo31064-fig-0014){ref-type="fig"}). (c) Antibiotic tolerance assays were performed like those shown in Figure [2](#mbo31064-fig-0002){ref-type="fig"}, and the fraction of ciprofloxacin‐tolerant cells 5 hr after inoculation was determined for cultures of *E. coli* CFT073 Δ*pasTI* harboring complementation plasmids encoding *cc1736* or *coq10* or the empty vector (ev). Time--kill curves at this time point showed biphasic killing, revealing that the differences in antibiotic tolerance reflect different levels of persister cells (Figure [A2a](#mbo31064-fig-0011){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). (d) The sensitivity of *E. coli* CFT073 Δ*pasTI* to treatment with hydrogen peroxide (H~2~O~2~) 2 hr after inoculation was determined for strains carrying *cc1736* or *coq10* complementation plasmids or the empty vector (ev) as shown in Figure [7c](#mbo31064-fig-0007){ref-type="fig"}. Unless indicated otherwise, all data points in (a‐d) represent the mean of results from at least three independent experiments and error bars indicate standard deviations. In all experiments, the P*lac* promoter on all plasmids was induced during overnight cultures and throughout the experiment by supplementing culture media with 1 mM IPTG.](MBO3-9-e1064-g008){#mbo31064-fig-0008}

4. DISCUSSION {#mbo31064-sec-0022}
=============

4.1. No evidence for links between PasT and PasI or a common function as a TA system {#mbo31064-sec-0023}
------------------------------------------------------------------------------------

Our study had initially been inspired by previous work proposing that PasT is a TA‐encoded toxin that inhibits ribosome assembly and somehow contributes to persister cell formation of uropathogenic *E. coli* (Norton & Mulvey, [2012](#mbo31064-bib-0057){ref-type="ref"}; Zhang & Inouye, [2011](#mbo31064-bib-0083){ref-type="ref"}). Given recent debates about the role of TA systems in antibiotic tolerance of *E. coli*, this was a very interesting result (Goormaghtigh et al., [2018](#mbo31064-bib-0024){ref-type="ref"}; Harms et al., [2017](#mbo31064-bib-0028){ref-type="ref"}; Shan et al., [2017](#mbo31064-bib-0065){ref-type="ref"}). However, we found no evidence for a link of PasT to either TA systems or ribosomes. Consistently, the data of a previous study also showed that expression of the PasT/RatA ortholog of *Salmonella* Typhimurium did not affect bacterial growth (Lobato‐Marquez, Moreno‐Cordoba, Figueroa, Diaz‐Orejas, & Garcia‐del Portillo, [2015](#mbo31064-bib-0046){ref-type="ref"}). The discrepancy between our results and earlier work reporting growth inhibition upon PasT expression may be explained by the very high overexpression of protein constructs in previous studies that is prone to interfere with cellular physiology. Consistently, severe overexpression of *coq10* in yeast inhibited cellular growth by interfering with mitochondrial respiration (Zampol et al., [2010](#mbo31064-bib-0081){ref-type="ref"}).

Our study also did not find evidence for a functional link between PasT and PasI, because phenotypes observed with Δ*pasTI* mutants could always be complemented by *pasT* and its homologs alone but never by its proposed antitoxin partner. Consistently, only *pasT* genes of beta‐ and gammaproteobacteria are accompanied by a *pasI* gene while solitary *pasT* (including mitochondrial *coq10*) is much more abundant (Figure [3](#mbo31064-fig-0003){ref-type="fig"}; Shen et al., [2005](#mbo31064-bib-0068){ref-type="ref"}; Tsui et al., [2019](#mbo31064-bib-0074){ref-type="ref"}). Future studies could therefore explore whether PasI might be an accessory factor to PasT that constitutes an evolutionary innovation in beta‐ and gammaproteobacteria or whether *pasI* is just a functionally unrelated protein that these lineages acquired and encoded next to *pasT* merely by chance.

4.2. Unification of the PasT/Coq10 family of StART domain proteins {#mbo31064-sec-0024}
------------------------------------------------------------------

Though we cannot exclude that PasT has a moonlighting function linked to ribosome assembly, multiple observations suggest that PasT is the bacterial equivalent of its mitochondrial homolog Coq10 that acts as an accessory factor in the ubiquinone‐dependent ETC: *E. coli* mutants lacking PasT/RatA display phenotypes linked to defective ubiquinone‐dependent electron transport that are similar to phenotypes observed for *coq10* mutants (Figures [4](#mbo31064-fig-0004){ref-type="fig"}, [5](#mbo31064-fig-0005){ref-type="fig"}, [6](#mbo31064-fig-0006){ref-type="fig"}, [7](#mbo31064-fig-0007){ref-type="fig"}), and these phenotypes can be largely complemented by human Coq10 (Figure [8](#mbo31064-fig-0008){ref-type="fig"}). Consistently, a prediction of potential functional partners for PasT/RatA using STRING ([https://string‐db.org/](https://string-db.org/); Szklarczyk et al., [2018](#mbo31064-bib-0072){ref-type="ref"}) retrieved many proteins involved in ubiquinone biosynthesis and the ETC but no ribosomal proteins (Figure [A4c](#mbo31064-fig-0013){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). From these results, we therefore conclude that PasT/RatA are not only homologous to Coq10 but at least to large extent functionally equivalent as "lipid chaperones" that arrange the utilization of ubiquinone in the ETC (recently reviewed by Awad et al., [2018](#mbo31064-bib-0007){ref-type="ref"}; Stefely & Pagliarini, [2017](#mbo31064-bib-0071){ref-type="ref"}).

These findings close one of the multiple gaps in our understanding of the electron transport chain and the functionality of ubiquinone that are widely conserved and thus relevant both for human diseases and---given the broad conservation of *pasT* among pathogenic Proteobacteria (Figure [3](#mbo31064-fig-0003){ref-type="fig"})---for antibiotic treatment (Aussel et al., [2014](#mbo31064-bib-0006){ref-type="ref"}; Hirose et al., [2019](#mbo31064-bib-0031){ref-type="ref"}; Stefely & Pagliarini, [2017](#mbo31064-bib-0071){ref-type="ref"}). Notably, eukaryotic ubiquinone biosynthesis and respiratory electron transport chain are mitochondrial pathways that have been acquired by the eukaryotic lineage from the primordial bacterial endosymbiont during its evolution from a proteobacterium into extant mitochondria (Andersson et al., [1998](#mbo31064-bib-0003){ref-type="ref"}; Stefely & Pagliarini, [2017](#mbo31064-bib-0071){ref-type="ref"}). We therefore anticipate that future studies on the PasT/Coq10 family might use the technically highly accessible *E. coli* system to unravel the molecular function of these proteins in ubiquinone‐dependent respiration that seems to be conserved from bacteria to humans.

4.3. Links between PasT, electron transport, and oxidative stress {#mbo31064-sec-0025}
-----------------------------------------------------------------

*E. coli* Δ*ratAB*/Δ*pasTI* mutants display several phenotypes linked to oxidative stress sensitivity or redox balance (Figure [4](#mbo31064-fig-0004){ref-type="fig"} and Figure [6](#mbo31064-fig-0006){ref-type="fig"}/Figure [7](#mbo31064-fig-0007){ref-type="fig"}) that correlates with modest defects in exponential‐phase ubiquinone biosynthesis as also previously observed for yeast *coq10* mutants (see above). However, it is not clear how defective respiration causes these phenotypes or what is the molecular function of Coq10 (Allan et al., [2013](#mbo31064-bib-0001){ref-type="ref"}; Awad et al., [2018](#mbo31064-bib-0007){ref-type="ref"}; Barros et al., [2005](#mbo31064-bib-0009){ref-type="ref"}; Cui & Kawamukai, [2009](#mbo31064-bib-0015){ref-type="ref"}; Stefely & Pagliarini, [2017](#mbo31064-bib-0071){ref-type="ref"}; Tsui et al., [2019](#mbo31064-bib-0074){ref-type="ref"}). In this regard, our study moves the understanding of PasT/RatA roughly to the point of how far the field understands Coq10.

Notably, the mild defect of *E. coli* CFT073 Δ*pasTI* in ubiquinone biosynthesis (Figure [5c](#mbo31064-fig-0005){ref-type="fig"}/d) was too weak to affect steady‐state ubiquinone levels (Figure [5a](#mbo31064-fig-0005){ref-type="fig"}). It therefore cannot explain the multiple phenotypes of *E. coli* Δ*pasTI*/Δ*ratAB* mutants that are linked to defective aerobic respiration given that, for example, the considerable reduction of ubiquinone levels in an *E. coli ubiI* mutant (ca. 15% of wild‐type) still enables normal respiration (Pelosi et al., [2016](#mbo31064-bib-0058){ref-type="ref"}). These strong pleiotropic phenotypes of PasT/RatA deficiency (and the lack of Coq10) are therefore likely caused by problems linked to the proposed role of these proteins as "lipid chaperones" that facilitate the implementation of ubiquinone at the electron transport chain (recently reviewed by Awad et al., [2018](#mbo31064-bib-0007){ref-type="ref"}; Stefely & Pagliarini, [2017](#mbo31064-bib-0071){ref-type="ref"}). Consequently, the observed phenotypes in ubiquinone biosynthesis might rather be downstream consequences---maybe via a feedback mechanism---of improperly utilized ubiquinone.

In general, impaired aerobic respiration often causes growth defects and a small‐colony phenotype specifically under aerobic conditions (Aussel et al., [2014](#mbo31064-bib-0006){ref-type="ref"}; Day, [2013](#mbo31064-bib-0016){ref-type="ref"}; Koskiniemi et al., [2011](#mbo31064-bib-0040){ref-type="ref"}; Poon et al., [2000](#mbo31064-bib-0061){ref-type="ref"}; Proctor et al., [2014](#mbo31064-bib-0062){ref-type="ref"}; Xia et al., [2017](#mbo31064-bib-0079){ref-type="ref"}). On the one hand, this observation could be explained by the poor energy metabolism of these mutants due to their limited ability to use oxygen as a terminal electron acceptor, while under anaerobic conditions other quinone electron shuttles serve other terminal acceptors or merely fermentation takes place instead. On the other hand, these observations could be explained as a consequence of reactive oxygen species (ROS) sensitivity and/or production. Consistently, *E. coli* K‐12 defective for ubiquinone production grows poorly under aerobic conditions where it shows signs of oxidative stress (Nitzschke & Bettenbrock, [2018](#mbo31064-bib-0056){ref-type="ref"}), and similar observations have been made for a yeast *coq10* mutant (Cui & Kawamukai, [2009](#mbo31064-bib-0015){ref-type="ref"}). These results could be explained by the pro‐ and antioxidant activities of different forms of ubiquinone, but the details of this relationship have not been resolved (Wang & Hekimi, [2016](#mbo31064-bib-0077){ref-type="ref"}). Also, defects in the electron transport chain cause leakage of electrons and uncontrolled formation of ROS that damages cellular macromolecules, a problem inherent to respiration, and linked to many human diseases (Jastroch, Divakaruni, Mookerjee, Treberg, & Brand, [2010](#mbo31064-bib-0036){ref-type="ref"}). We anticipate that future studies unraveling the precise biological function of PasT/Coq10 in the context of ubiquinone‐dependent respiration will also reveal how the lack of its activity is linked to oxidative stress and cellular redox balance in bacteria and humans.

4.4. PasT highlights the importance of electron transport for bacterial persister cells {#mbo31064-sec-0026}
---------------------------------------------------------------------------------------

The initial focus of our study was to understand the specific defect of uropathogenic *E. coli* CFT073 lacking *pasTI* in the formation or survival of persister cells (Norton & Mulvey, [2012](#mbo31064-bib-0057){ref-type="ref"}). We readily reproduced this phenotype in *E. coli* CFT073 itself and different pathogenic *E. coli* strains as well as *Salmonella* Typhimurium (Figure [2](#mbo31064-fig-0002){ref-type="fig"} as well as Figures [A2](#mbo31064-fig-0011){ref-type="fig"} and [A3](#mbo31064-fig-0012){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). However, our results also showed that PasTI is not just a genetic switch controlling transition into dormancy as a TA module would supposedly be. Instead, PasT seems to be deeply wired into bacterial redox balance and energy metabolism through its role as a facilitator of ubiquinone‐dependent respiration (Figure [9](#mbo31064-fig-0009){ref-type="fig"}). The link of PasT to antibiotic tolerance is therefore likely indirect and mediated through broad distortions of bacterial physiology caused by defective aerobic respiration.

![Working model: *pasT* deficiency causes pleiotropic phenotypes by interfering with ubiquinone‐dependent respiration. The illustration summarizes and interprets the main results of our study. In the absence of PasT, membrane potential, resilience to oxidative stress, and (for pathogenic *E. coli* as well as *Salmonella* Typhimurium) levels of antibiotic‐tolerant persisters are reduced (Figure [2](#mbo31064-fig-0002){ref-type="fig"}/Figures [4](#mbo31064-fig-0004){ref-type="fig"}, [5](#mbo31064-fig-0005){ref-type="fig"}, [6](#mbo31064-fig-0006){ref-type="fig"}, [7](#mbo31064-fig-0007){ref-type="fig"} and Figure [A2](#mbo31064-fig-0011){ref-type="fig"}/Figure [A3](#mbo31064-fig-0012){ref-type="fig"}/Figure [A5](#mbo31064-fig-0014){ref-type="fig"}/Figure [A6](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). These phenotypes are---similar to findings for yeast *coq10* mutants---likely caused by defective aerobic respiration due to impaired ubiquinone functionality at the electron transport chain (Figure [4](#mbo31064-fig-0004){ref-type="fig"}/Figure [8](#mbo31064-fig-0008){ref-type="fig"})](MBO3-9-e1064-g009){#mbo31064-fig-0009}

A general link between persister formation and ETC functionality is well established; various mutations in ETC components can show both increased and decreased levels of persisters (Harms et al., [2016](#mbo31064-bib-0029){ref-type="ref"}; Shan, Lazinski, Rowe, Camilli, & Lewis, [2015](#mbo31064-bib-0066){ref-type="ref"}; Van den Bergh et al., [2016](#mbo31064-bib-0075){ref-type="ref"}). However, the physiological basis of this link and the underlying molecular mechanisms are poorly understood. One possibility is that the ETC could modulate persister levels by affecting ATP production since persister formation can be associated with decreased ATP levels (Shan et al., [2017](#mbo31064-bib-0065){ref-type="ref"}). However, impaired electron transport upon PasT deficiency should then rather cause increased persister formation by limiting cellular ATP production. Alternatively, it has been hypothesized repeatedly that bacterial killing by various antibiotics is causally linked to the generation of ROS by a hyperactivated ETC in response to metabolic perturbations (Kohanski, Dwyer, & Collins, [2010](#mbo31064-bib-0039){ref-type="ref"}; Yang, Bening, & Collins, [2017](#mbo31064-bib-0080){ref-type="ref"}), though these ideas have been disputed by others (Keren, Wu, Inocencio, Mulcahy, & Lewis, [2013](#mbo31064-bib-0038){ref-type="ref"}; Liu & Imlay, [2013](#mbo31064-bib-0045){ref-type="ref"}). This view would suggest that the decreased antibiotic tolerance upon *pasT* deficiency is linked to drug‐induced ROS production and ultimately rooted in a general hypersensitivity to ROS. Consistently, mechanisms involved in reducing oxidative stress and increasing ROS detoxification have been linked previously to persister survival in *E. coli* CFT073 and other bacteria (Molina‐Quiroz, Lazinski, Camilli, & Levy, [2016](#mbo31064-bib-0053){ref-type="ref"}; Nguyen et al., [2011](#mbo31064-bib-0055){ref-type="ref"}).

Critically, none of these hypotheses can explain why the four *E. coli* strains investigated in this work as well as *Salmonella* Typhimurium share most phenotypes linked to *pasT*/*ratA* deficiency except for the persister defect that is specifically absent in the *E. coli* K‐12 MG1655 laboratory strain (Figure [2](#mbo31064-fig-0002){ref-type="fig"}/Figure [4](#mbo31064-fig-0004){ref-type="fig"}/Figure [6](#mbo31064-fig-0006){ref-type="fig"}/Figure [7](#mbo31064-fig-0007){ref-type="fig"} and Figure [A2](#mbo31064-fig-0011){ref-type="fig"}/Figure [A3](#mbo31064-fig-0012){ref-type="fig"}/Figure [A5](#mbo31064-fig-0014){ref-type="fig"}/Figure [A6](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). Also, the *E. coli* K‐12 Δ*ratAB* mutant did not show the modest defect in exponential‐phase ubiquinone biosynthesis that was readily apparent for *E. coli* CFT073 Δ*pasTI* (Figure [5d](#mbo31064-fig-0005){ref-type="fig"}). Before testing the other strains beyond *E. coli* K‐12 and CFT073, we initially suspected that the widespread use of strains carrying *rpoS* loss‐of‐function alleles (*rpoS~am~*) as *E. coli* CFT073 "wild‐type" might explain the increased sensitivity of this strain compared to K‐12 MG1655 (Hryckowian, Baisa, Schwartz, & Welch, [2015](#mbo31064-bib-0033){ref-type="ref"}; Hryckowian & Welch, [2013](#mbo31064-bib-0034){ref-type="ref"}) since RpoS is a central player in *E. coli* stress responses (Battesti, Majdalani, & Gottesman, [2011](#mbo31064-bib-0010){ref-type="ref"}). Targeted sequencing of *rpoS* indeed confirmed that our *E. coli* CFT073 strain carried the *rpoS~am~* allele. However, control experiments with a variant carrying intact *rpoS* found no differences in antibiotic tolerance and all other phenotypes to our original data beyond a change in the dynamics of H~2~O~2~ survival that in this strain look much more similar to *E. coli* K‐12 MG1655 (Figure [A7](#mbo31064-fig-0016){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}). These results suggest that RpoS‐controlled stress responses can buffer against some of the distortions of bacterial physiology that are caused by a lack of PasT but do not explain the severe defect of *E. coli* CFT073 Δ*pasTI* in antibiotic tolerance. Given that this defect and all other phenotypes are also shared by different pathogenic *E. coli* as well as *Salmonella* Typhimurium (Figure [A3](#mbo31064-fig-0012){ref-type="fig"}/Figure [A5](#mbo31064-fig-0014){ref-type="fig"}/Figure [A6](#mbo31064-fig-0015){ref-type="fig"} in Appendix [2](#mbo31064-app-0002){ref-type="app"}), it is likely to be more representative of enterobacteria while the divergent behavior of *E. coli* K‐12 MG1655 might be related to one or more features of the peculiar physiology of this laboratory‐adapted strain (Hobman, Penn, & Pallen, [2007](#mbo31064-bib-0032){ref-type="ref"}).
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List of all strains used in this study

  Strain    Genotype                                                                       Source/description
  --------- ------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CF323     *Escherichia coli* K‐12 MG1655: F^--^ λ^--^ *ilvG* ^--^ *rfb‐50 rph‐1*         Wild‐type strain; Gerdes laboratory collection
  EG94      *E. coli* K‐12 MG1655 *ΔhipAB::*FRT pBAD33 P*araB*:: SD4 *atg hipA*            MG1655 *hipAB*::FRT harboring pBAD33 P*araB*:: SD4 *atg hipA* (Germain et al., [2013](#mbo31064-bib-0021){ref-type="ref"})
  CF083     *E. coli* K‐12 MG1655 *ΔratAB*                                                 This study; derivative of *E. coli* K‐12 MG1655 with scarless deletion of *ratAB*
  CF002     *Escherichia coli* CFT073: *hly^+^ pap*1^+^ *sfa*1^+^ *pil*1^+^ (*rpoS~am~*)   Obtained from Anders Løbner‐Olesen; a 5 bp duplication (TAGAG) at the 3′ end of *c3307* ORF causes a frameshift and premature amber stop codon in *rpoS* as reported earlier (Hryckowian et al., [2015](#mbo31064-bib-0033){ref-type="ref"}); used throughout most of this study
  CF069     *E. coli* CFT073 *ΔpasTI* (*rpoS~am~*)                                         This study; derivative of CF002 with scarless deletion of *pasTI*; used throughout most of this study
  CF370     *E. coli* CFT073 (intact *rpoS*)                                               *E. coli* CFT073 wild‐type with intact *rpoS*; obtained from Daniel R. Brown, Imperial College London (UK)
  CF378     *E. coli* CFT073 *ΔpasTI* (intact *rpoS*)                                      This study; derivative of CF370 with scarless deletion of *pasTI*
  ALO3978   *E. coli* GM9255 EDL933 (933w Δstx2AB::kan)                                    Anders Løbner‐Olesen laboratory collection; attenuated version of *E. coli* O157:H7 strain EDL933 with deletion of the Shiga toxin (Marinus & Poteete, [2013](#mbo31064-bib-0050){ref-type="ref"})
  CF583     EDL933 *ΔpasTI*                                                                This study; derivative of ALO3978 with scarless deletion of *pasTI*
  CF555     *E. coli* 55989                                                                Obtained from Karen A. Krogfelt, Roskilde University (DK)
  CF598     *E. coli* 55989 *ΔpasTI::*FRT                                                  This study; derivative of CF555 after disruption of *pasTI* locus with an FRT‐*km*FRT selectable cassette, then flipped out
  CF557     *Salmonella enterica* serovar *enterica* str. SR‐11                            Obtained from Karen A. Krogfelt, Roskilde University (DK)
  CF587     SR‐11 *ΔpasTI*                                                                 This study; derivative of CF557 with scarless deletion of *pasTI*
  CF574     *E. coli* K‐12 MG1655 *ΔubiA*::*cat*                                           Pierrel laboratory collection (Pelosi et al., [2019](#mbo31064-bib-0059){ref-type="ref"})
  CF575     *E. coli* K‐12 MG1655 *ΔubiX*::*km*                                            Pierrel laboratory collection (Pelosi et al., [2019](#mbo31064-bib-0059){ref-type="ref"})

John Wiley & Sons, Ltd

###### 

List of all plasmids used in this study

  Identifier                       Plasmid                       Genotype/selection                                                        Source/description/construction
  -------------------------------- ----------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  n.a.                             pNDM220                       mini‐R1 ori; *bla*; *lacI^q^*; P*lac* promoter. Amp 30 µg/ml              Gerdes laboratory collection
  n.a.                             pBAD33                        pA15 ori; *cat; araC*; P*araB* promoter. Cam 25 µg/ml                     Gerdes laboratory collection
  n.a.                             pWRG99                        TS ori; *bla*; P*araB* promoter; λred. Amp 100 µg/ml                      (Blank et al., [2011](#mbo31064-bib-0012){ref-type="ref"}); recombineering plasmid
  n.a.                             pKO4/pELO4                    Cam 25 µg/ml                                                              (Lee et al., [2001](#mbo31064-bib-0042){ref-type="ref"}); template plasmid for amplification of the *cat‐sacB* cassette for recombineering
  n.a.                             pKM208                        TS ori; *bla;* P*lac* promoter; λred Amp 100 µg/ml                        (Murphy & Campellone, [2003](#mbo31064-bib-0054){ref-type="ref"}); recombineering plasmid
  n.a.                             pCP20                         TS ori; *bla;* Amp 100 µg/ml                                              Gerdes laboratory collection; plasmid used to flip out the resistance cassette upon expression of the flippase (FLP) at 30°C
  n.a.                             pKD3                          Amp 30 µg/ml; Cam 25 30 µg/ml                                             Gerdes laboratory collection; template plasmid for amplification of the *FRT*‐*cat‐FRT* cassette for recombineering
  n.a.                             pKD13                         Amp 30 µg/ml; Km 25 30 µg/ml                                              Gerdes laboratory collection; template plasmid for amplification of the *FRT*‐*km‐FRT* cassette for recombineering
  n.a.                             pAH186_ColE1                  ColE1 ori; *bla*; *lacI^q^*; P*lac* promoter. Amp 100 µg/ml               This study; derivative of pNDM220 with ColE1 *ori* (copy number 15‐20) instead of mini‐R1; the ColE1 *ori* was amplified from pBR322 (our collection) with primers prAH1206/prAH1207, and a fragment comprising *bla‐lacI^q^*‐P*lac* was amplified from pNDM220 with primers prAH1202/prAH1203; the PCR products were ligated after restriction digest with NsiI and HindIII
  n.a.                             pAH186_SC101                  SC101 ori; *bla*; *lacI^q^*; P*lac* promoter. Amp 100 µg/ml               This study; derivative of pNDM220 with SC101 *ori* (copy number \~5) instead of mini‐R1; the SC101 *ori* was amplified from pUA139 (Zaslaver et al., [2006](#mbo31064-bib-0082){ref-type="ref"}) with primers prAH1204/prAH1205, and a fragment comprising *bla‐lacI^q^*‐P*lac* was amplified from pNDM220 with primers prAH1202/prAH1203; the PCR products were ligated after restriction digest with NsiI and HindIII
  Inducible *pasT* (low copy)      pCF001\_*pasT*\_v~1~          Derivative of pNDM220 encoding *pasT*. Amp 30 µg/ml                       This study; the *pasT* ORF was amplified from *E. coli* CFT073 with a strong RBS and a GTG SC (AGGAGAaacaattttGTG) using primers prCF070/prCF071 and ligated into pNDM220 downstream P*lac* after digestion of backbone and insert with BamHI/EcoRI. The GTG has been converted into ATG by site‐directed mutagenesis using primers prCF291/prCF292. IPTG induction of *pasT* expression.
  Inducible *pasT* (high copy)     pAH186_ColE1\_*pasT_v~1~*     Derivative of pAH186_ColE1 encoding *pasT* ~.~ Amp 100 µg/ml              This study; the *pasT* ORF was amplified from *E. coli* CFT073 with a strong RBS and a GTG SC (AGGAGAaacaattttGTG) using primers prCF070/prCF071 and ligated into pAH186_ColE1 downstream P*lac* after digestion of backbone and insert with BamHI/EcoRI. The GTG has been converted into ATG by site‐directed mutagenesis using primers prCF291/prCF292. IPTG induction of *pasT* expression
  Inducible *pasT* (medium copy)   pAH186_SC101\_*pasT_v~1~*     Derivative of pAH186_SC101 encoding *pasT* ~.~ Amp 100 µg/ml              This study; the *pasT* ORF was amplified from *E. coli* CFT073 with a strong RBS and a GTG SC (AGGAGAaacaattttGTG) using primers prCF070/prCF071 and ligated into pAH186_SC101 downstream P*lac* after digestion of backbone and insert with BamHI/EcoRI. The GTG has been converted into ATG by site‐directed mutagenesis using primers prCF291/prCF292. IPTG induction of *pasT* expression
  pdoc                             pAH154_doc_v2                 Derivative of pNDM220 encoding doc. Amp 30 µg/ml                          This study; the ORF of doc was amplified from bacteriophage P1vir with a weak RBS (ATTCCTCCaacaattttATG) using primers prAH1542/prAH1541 and ligated into pNDM220 downstream Plac after digestion of backbone and insert with KpnI/XhoI. IPTG induction of doc expression
  ppasTI                           pCF006_pasTI_v1               Derivative of pNDM220 encoding pasTI. Amp 30 µg/ml                        This study; pasTI operon including ≈300 bp upstream was amplified from *E. coli* CFT073 using primers prCF222/prCF223 and ligated into pNDM220 after digestion of backbone and insert with BamHI/EcoRI. V1 = strong SD and original SC (ATG). Expression of pasTI under endogenous transcriptional control
  pratAB                           pCF006_ratAB_v1               Derivative of pNDM220 encoding ratAB. Amp 30 µg/ml                        This study; ratAB operon including ≈300 bp upstream was amplified from *E. coli* MG1655 using primers prCF222/prCF224 and ligated into pNDM220 after digestion of backbone and insert with BamHI/EcoRI. V1 = strong SD and original SC (ATG). Expression of ratAB under endogenous transcriptional control
  ppasT                            pCF006_pasT_v1                Derivative of ppasTI (pCF006_pasTI_v1) encoding only pasT. Amp 30 µg/ml   This study; pasI ORF was deleted from ppasTI by site‐directed mutagenesis using primers prCF236/prCF237
  pratA                            pCF006_ratA_v1                Derivative of pratAB (pCF006_ratAB_v1) encoding only ratA. Amp 30 µg/ml   This study; ratB ORF was deleted from pratAB by site‐directed mutagenesis using primers prCF236/prCF240
  pratB                            pCF006_ratB_v1                Derivative of pratAB (pCF006_ratAB_v1) encoding only ratB. Amp 30 µg/ml   This study; ratA ORF was deleted from pratAB by site‐directed mutagenesis using primers prCF238/prCF239
  pCC1736                          pCF007_cc1736_v1              Derivative of pNDM220 encoding cc1736. Amp 30 µg/ml                       This study; codon‐optimized cc1736 ORF was synthesized by GenScript, amplified using primers prCF256/prCF257, and ligated into pNDM220 downstream of Plac after digestion of backbone and insert with BamHI/XhoI digestion. V1 = strong RBS and original start codon (CTG). IPTG induction of cc1736 expression
  pCOQ10                           pCF007_coq10_v4               Derivative of pNDM220 encoding coq10A. Amp 30 µg/ml                       This study; codon‐optimized coq10 ORF (isoform A) was synthesized by GenScript, amplified using primers prCF259/prCF290, and ligated into pNDM220 downstream Plac after digestion of backbone and insert with BamHI/XhoI. V4 = N‐terminus truncated variant. IPTG induction of coq10A expression
  ppasI                            pCF003_pasI_v1                Derivative of pBAD33 encoding pasI. Cam 25 µg/ml                          This study; pasI ORF was amplified from *E. coli* CFT073 with a strong RBS and a GTG SC (AGGAGAaacaattttGTG) using primers prCF166/prCF251 and ligated into pBAD33 downstream ParaB after digestion of backbone and insert with HindIII/XbaI. Arabinose induction of pasI expression. V1 = original SC (GTG) and strong RBS
  phipA                            pBAD33 ParaB:: SD4 atg hipA   Derivative of pBAD33 encoding hipA. Cam 25 µg/ml                          Gerdes laboratory collection. hipA ORF was amplified from *E. coli* K‐12 MG1655 with a strong RBS and an ATG SC (AAGGAaaaaATG) using primers OEG89/OEG60 (Germain et al., [2013](#mbo31064-bib-0021){ref-type="ref"}) and ligated into pBAD33 downstream ParaB promoter after digestion of backbone and insert with XbaI/SphI. Arabinose induction of hipA expression

Abbreviations: Amp, Ampicillin; *araC*, encodes the regulator of P*araB*; *bla*, β‐lactamase‐encoding cassette; Cam, Chloramphenicol; *cat*, Chloramphenicol acetyltransferase; IPTG, Isopropyl β‐[d]{.smallcaps}‐1‐thiogalactopyranoside; Kan, Kanamycin; *lacI^q^*, encodes the repressor of P*lac* (allele with strong *lacI* expression); ori, plasmid origin of replication; P*araB*, promoter inducible with L‐arabinose; P*lac*, Promoter inducible with IPTG; RBS, Ribosome binding site; SC, Start codon; TS, temperature‐sensitive; λ*red*, recombineering system.
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Oligonucleotides used in this study

  Oligo name                                                     Sequence                                                                            Description
  -------------------------------------------------------------- ----------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  *pasTI/ratAB* deletion                                                                                                                             
  prCF025                                                        GTGCTCAATGAGCACCTTTTTTCTGTCTGTTATTTATTCGCTGATTTTTC[CTGGTGTC CCTGTTGATACC]{.ul}      rv. MG1655/CFT073. Amplification of *cat‐sacB* cassette. Homology to the cassette is highlighted
  prCF026                                                        CCGATGTTACCCAGCGCCGGGATAGCGTTTTTTTTACAGCAGGATAAATG[GGAAAA CTGTCCATATGCAC]{.ul}      fw. MG1655/CFT073. Amplification of *cat‐sacB* cassette; Homology to the cassette is highlighted
  prCF027                                                        AGCACCTTTTTTCTGTCTGTTATTTATTCGCTGATTTTTCCATTTATCCTGCTGTAAAA AAAACGCTATCCCGGCGCTGG   rv. MG1655/CFT073. Scarless deletion of the *cat‐sacB* cassette
  prCF028                                                        CCAGCGCCGGGATAGCGTTTTTTTTACAGCAGGATAAATGGAAAAATCAGCGAAT AAATAACAGACAGAAAAAAGGTGCT   fw. MG1655/CFT073. Scarless deletion of the *cat‐sacB* cassette
  prCF323                                                        GTGCTCAATGAGCACCTTTTTTCTGTCCGTTATTTATTCGCTGATTTTTC[CTGGTGTC CCTGTTGATACC]{.ul}      rv. EDL933. Amplification of *cat‐sacB* cassette. Homology to the cassette is highlighted
  prCF324                                                        GGATGTTACCCAGCGCCGGGATAGCGTTTTTTTTACTGCAGGATAAATG[GGAAAAC TGTCCATATGCAC]{.ul}       fw. EDL933. Amplification of *cat‐sacB* cassette. Homology to the cassette is highlighted
  prCF325                                                        AGCACCTTTTTTCTGTCCGTTATTTATTCGCTGATTTTTCCATTTATCCTGCAGTAAA AAAAACGCTATCCCGGCGCTGG   rv. EDL933. Scarless deletion of the *cat‐sacB* cassette
  prCF326                                                        CCAGCGCCGGGATAGCGTTTTTTTTACTGCAGGATAAATGGAAAAATCAGCGAATA AATAACGGACAGAAAAAAGGTGCT   fw. EDL933. Scarless deletion of the *cat‐sacB* cassette
  prCF329                                                        CCACACCGTTATCCGGCAAAAGAGGCTAATTATCTGCCAGCCGATTTTTC[CTGGTGT CCCTGTTGATACC]{.ul}      rv. SR11. Amplification of *cat‐sacB* cassette. Homology to the cassette is highlighted
  prCF330                                                        ATTAAGGCATGACGGTTGGGGACAGCATTTTTTTTACTCGCTGATAAGTG[GGAAAA CTGTCCATATGCAC]{.ul}      fw. SR11. Amplification of *cat‐sacB* cassette. Homology to the cassette is highlighted
  prCF331                                                        ATCCGGCAAAAGAGGCTAATTATCTGCCAGCCGATTTTTCCACTTATCAGCGAGTA AAAAAAATGCTGTCCCCAACCGTC   rv. SR11. Scarless deletion of the *cat‐sacB* cassette
  prCF332                                                        GACGGTTGGGGACAGCATTTTTTTTACTCGCTGATAAGTGGAAAAATCGGCTGGCA GATAATTAGCCTCTTTTGCCGGAT   fw. SR11. Scarless deletion of the *cat‐sacB* cassette
  prCF231                                                        GTGCTCAATGAGCACCTTTTTTCTGTCTGTTATTTATTCGCTGATTTTTC[TGTAGGCT GGAGCTGCTTCG]{.ul}      rv. 55989. Amplification of FRT‐*km*‐FRT cassette. Homology to the cassette is highlighted
  prCF232                                                        CCGATGTTACCCAGCGCCGGGATAGCGTTTTTTTTACAGCAGGATAAATG[ATTCCG GGGATCCGTCGACC]{.ul}      fw. 55989. Amplification of FRT‐*km*‐FRT cassette. Homology to the cassette is highlighted
  prCF023                                                        GAACTATCTGACCGCTAACGAC                                                              rv. Screening *pasTI/ratAB* locus
  prCF024                                                        GTCGCGCAGAAGGAC                                                                     fw. Screening *pasTI* locus
  prCF033                                                        GAAATGCCTCTCCGTCAC                                                                  fw. Screening *ratAB* locus and *pasTI* locus of 55989
  prCF327                                                        GGAACTATCTTACACCTACGGAT                                                             rv. SR11. Screening *pasTI* locus
  prCF328                                                        CGCCATCTTTGAGGATAAC                                                                 fw. SR11. Screening *pasTI* locus
  pCF001\_*pasT*\_v~1~ construction and related plasmids                                                                                             
  prCF070                                                        CCCGAGGGATCCAGGAGAAACAATTTTGTGATATTATTTGTTGGATTTTTGTTG                              fw. Amplification of *pasT* gene. BamHI RS
  prCF071                                                        GGGCTCGAATTCTTACCTGGCACTGTAGACCTC                                                   rv. Amplification of *pasT* gene. EcoRI RS
  prCF291                                                        ACAATTTTATGATATTATTTGTTGGATTTTTGTTG                                                 fw. GTG to ATG conversion
  prCF292                                                        TAATATCATAAAATTGTTTCTCCTGGATCC                                                      rv; GTG to ATG conversion
  pCF006\_*pasTI*\_v~1~ and pCF006\_*ratAB*\_v~1~ construction                                                                                       
  prCF222                                                        ACCGAGGGATCCAGGAGAAACAATTTTGGACATAGCTGTCGCTGATA                                     fw. Amplification of *pasTI* operon. BamHI RS
  prCF223                                                        GGGCTCGAATTCTTATTTATTCGCTGATTTTTCTG                                                 rv. Amplification of *pasTI/ratAB* operon. EcorI RS
  prCF224                                                        ACCGAGGGATCCAGGAGAAACAATTTTGGACGTAGCTGTCGCTG                                        fw. Amplification of ratAB operon. BamHI RS
  pCF006\_*pasT*\_v~1~ and pCF006\_*ratA*\_v~1~ construction                                                                                         
  prCF236                                                        TGCCAGGTAAGAATTCACTGGCCGTCG                                                         fw. Deletion of *pasI/ratB* from pCF006\_*pasTI/ratAB*\_v~1~
  prCF237                                                        AGTGAATTCTTACCTGGCACTGTAGACCTC                                                      rv. Deletion of *pasI* from pCF006\_*pasTI*\_v~1~
  prCF240                                                        AGTGAATTCTTACCTGGCACTGTAAACCTC                                                      rv. Deletion of ratB from pCF006_ratAB_v1
  pCF006\_*ratB*\_v~1~ construction                                                                                                                  
  prCF238                                                        AGCAGGATAAGTGCCAGGTAAAATTGCC                                                        fw. Deletion of *ratA* from pCF006\_*ratAB*\_v~1~
  prCF239                                                        TACCTGGCACTTATCCTGCTGTAAAAAAAACG                                                    rv. Deletion of *ratA* from pCF006\_*ratAB*\_v~1~
  pCF003\_*pasI*\_v~1~ construction                                                                                                                  
  prCF166                                                        GGGCTGAAGCTTTTATTTATTCGCTGATTTTTCTG                                                 rv. Amplification of *pasI*. HindIII RS
  prCF251                                                        CCCGAGTCTAGAAGGAGAAACAATTTTGTGCCAGGTAAAATTGCC                                       fw. Amplification of *pasI*. XbaI RS
  pCF007\_*cc1736*\_v~1~ construction                                                                                                                
  prCF256                                                        CCCGAGGGATCCAGGAGAAACAATTTTCTGCACCGTCACGTGG                                         fw. Amplification of *cc1736*. BamHI RS
  prCF257                                                        GGGCTCCTCGAGTTACGCACCATGCAGTTG                                                      rv. Amplification of *cc1736*. XhoI RS
  pCF007\_*coq10*\_v~4~ construction                                                                                                                 
  prCF259                                                        GGGCTCCTCGAGTTAGGTTTGGTGAACTTCGT                                                    rv. Amplification of *coq10A*. XhoI RS
  prCF290                                                        CAAGAGGGATCCAGGAGAAACAATTTTATGGCGTACAGCGAGCGT                                       fw. Amplification of *coq10A*. BamHI RS
  Others                                                                                                                                             
  prAH_pNDM220                                                   AAAACAGGAAGGCAAAATGC                                                                fw. Screening for cloning in pNDM220
  prAH500                                                        CTGTTTTATCAGACCGCTTC                                                                Rv. Screening for cloning in pNDM220 and pBAD33
  prAH501                                                        CGTCACACTTTGCTATGCC                                                                 fw. Screening for cloning in pBAD33
  prCF262                                                        GTTGTTTATGCCGGTAACG                                                                 fw. *rpoS* sequencing
  prCF263                                                        CAATTACTGTGCGCTTAAAATG                                                              rv. *rpoS* sequencing
  prAH1541                                                       GCCTTCCCTCGAGCTACTCCGCAGAACCATACAA                                                  rv. Amplification of *doc* from phage P1*vir*. XhoI RS
  prAH1542                                                       CGAGTGGGTACCATTCCTCCAACAATTTTATGAGGCATATATCACCGGA                                   fw. Amplification of *doc* from phage P1*vir*. KpnI RS
  prAH1202                                                       GACGCCAAGCTTCCTAGATCCTTTTAAATTAAAAATGAAG                                            fw. pNDM220 for pAH186 series
  prAH1203                                                       CTCCCGGATGCATGAAGCATAAAGTGTAAAGCCTG                                                 rv. pNDM220 for pAH186 series
  prAH1204                                                       GACGCCATGCATCCGCTGTAACAAGTTGTCTC                                                    fw. SC101 for pAH186 series
  prAH1205                                                       CTCCCGGAAGCTTCGCTTGGACTCCTGTTG                                                      rv. SC101 for pAH186 series
  prAH1206                                                       GAGCGGATGCATAGTGATTTTTCTCTGGTCCC                                                    fw. ColE1 for pAH186 series
  prAH1207                                                       CTCCGCCAAGCTTCCCGTAGAAAAGATCAAAGG                                                   rv. ColE1 for pAH186 series
  prAH1805                                                       GGTTGTCTGCAGCATAAAGTGTAAAGCCTGGGG                                                   rv. pNDM220 inserts into pAH160‐P*lac*

Abbreviations: fw, Forward primer; rv, Reverse primer.
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Genomes used for the synteny analysis of Figure [3](#mbo31064-fig-0003){ref-type="fig"}

  Organism                                   Strain                                              GenBank/RefSeq accession number
  ------------------------------------------ --------------------------------------------------- ------------------------------------------
  *Escherichia coli*                         str. K‐12; substr. MG1655                           **U00096.3**/NC_000913.3
  *Escherichia coli*                         str. CFT073                                         **AE014075.1**/NC_004431.1
  *Escherichia coli*                         str. B; substr. REL606/Bc251                        **CP000819.1**/NC_012967.1
  *Escherichia coli*                         str. UTI89                                          **CP000243.1**/NC_007946.1
  *Shigella flexneri*                        serotype 5a str. M90T                               **CM001474.1**/NZ_CM001474.1
  *Salmonella enterica*                      subsp. *enterica;* serovar Typhimurium; str. CT18   **AL513382.1**/NC_003198.1
  *Pseudomonas aeruginosa*                   str. PAO1                                           **AE004091.2**/NC_002516.2
  *Burkholderia cenocepacia*                 str. J2315                                          Chromosome 1: **AM747720.1**/NC_011000.1
  Chromosome 2: **AM747721.1**/NC_011001.1                                                       
  *Neisseria meningitidis*                   serogroup B; str. MC58                              **AE002098.2**/NC_003112.2
  *Caulobacter crescentus*                   str. CB15/ATCC 19089                                **AE005673.1**/NC_002696.2
  *Myxococcus xanthus*                       str. DK 1622                                        **CP000113.1**/NC_008095.1
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 {#mbo31064-sec-0034}

![No growth inhibition is observed upon expression of *pasT* (and *pasI*) under different conditions. (a) Spot assay of *E. coli* CFT073 Δ*pasTI* mutant harboring isogenic plasmids with different copy number encoding either *pasT* or the well‐studied TA module toxin *doc* (as positive control) under control of a P*lac* promoter induced on LB agar plates containing 1 mM isopropyl β‐[d]{.smallcaps}‐1‐thiogalactopyranoside (IPTG) and repressed on LB agar plates containing 1% w/v [d]{.smallcaps}‐glucose (see Materials and Methods). The expression of *pasT* did not cause growth inhibition under any condition. (b) The same experiment as shown in (a) for *E. coli* CFT073 *ΔpasTI* was performed with *E. coli* K‐12 MG1655 wild‐type (top)/Δ*ratAB* (bottom). No growth inhibition was detected for *pasT* expression under any condition. (c) Spot assay of *E. coli* K‐12 MG1655 Δ*ratAB* harboring a plasmid encoding either *pasI* or the well‐studied TA module toxin *hipA* (as positive control) under control of a P*araB* promoter induced on agar plates containing 0.2% w/v L‐arabinose and repressed on agar plates containing 1% w/v [d]{.smallcaps}‐glucose (see Materials and Methods). No growth inhibition was detected for *pasI* expression](MBO3-9-e1064-g010){#mbo31064-fig-0010}

![Biphasic time--kill curves reveal differences in persister levels between *E. coli* CFT073 and the Δ*pasTI* mutant. (a) The figure shows the time--kill curves of *E. coli* CFT073 (left) and *E. coli* K‐12 MG1655 (right) strains treated with 10 μg/ml ciprofloxacin 5 hr after inoculation into fresh medium (see Materials and Methods). (b) The same experiment as presented in Figure [2a,b](#mbo31064-fig-0002){ref-type="fig"} for the dynamics of ciprofloxacin‐tolerant cells was repeated for treatment with 6.6 μg/ml colistin, revealing lower survival of *E. coli* CFT073 Δ*pasTI* (but not/K12 MG1655 *ΔratAB*) during exponential growth when compared to the parental wild‐type. Note that all strains seem to exhibit some resistance to colistin when the cultures reach high densities (i.e., later than the time points where differences between CFT073 wild‐type and *ΔpasTI* become apparent). We suggest that this phenomenon might be caused by the heterogeneous absorption of colistin in a way that a subpopulation of nongrowing cells sequesters enough drug to enable residual growth of other cells during the treatment period (as shown before for antimicrobial peptide LL37 by Snoussi et al. ([2018](#mbo31064-bib-0069){ref-type="ref"})). (c) The same experiment as presented in Figure [2a,b](#mbo31064-fig-0002){ref-type="fig"} for the dynamics of ciprofloxacin‐tolerant cells was repeated for treatment with 100 μg/ml ampicillin (as previously reported for Δ*pasTI* and Δ*ratAB* mutants by Norton and Mulvey ([2012](#mbo31064-bib-0057){ref-type="ref"})). (d) The figure shows time--kill curves of *E. coli* CFT073 strains treated with 6.6 μg/ml colistin after 2 hr of growth, that is, before any of the cultures have reached high densities. (e) The figure shows time--kill curves of *E. coli* CFT073 strains treated with 100 μg/ml ampicillin after 2 hr of growth, that is, at the minimal survival observed for both wild‐type and Δ*pasTI* mutant (see (c)). The regrowth observed after 3 hr in similar ways for both strains is likely due to the high intrinsic resistance of *E. coli* CFT073 to β‐lactams. (f) The complementation of decreased colistin survival of *E. coli* CFT073 Δ*pasTI* was confirmed by comparing the mutant strain carrying an empty vector with an isogenic strain harboring a plasmid encoding *pasT* for complementation. All data points in (a‐f) represent the mean of results from at least three independent experiments, and error bars indicate standard deviations. ev = empty vector (pNDM220)](MBO3-9-e1064-g011){#mbo31064-fig-0011}

![Differences in persister levels are observed between wild‐type and Δ*pasTI* variants of other *E. coli/Salmonella* strains. (a) The same experiment as presented in Figure [2a‐d](#mbo31064-fig-0002){ref-type="fig"} for the dynamics of *E. coli* CFT073 ciprofloxacin‐tolerant cells was repeated for *E. coli* O157:H7 EDL933 (top left), *E. coli* 55989 (top right), and *Salmonella enterica* SR‐11 (bottom). (b, c) Time--kill curves for *E. coli* EDL933 and *S. enterica* SR‐11 strains treated with 10 μg/ml ciprofloxacin 5 hr after inoculation into fresh medium reveal that the antibiotic tolerance defect of *pasTI* mutants can be complemented by ectopic expression of CFT073 *pasT*. We note that there are quantitative differences in the results of seemingly similar experiments in (a) and (b) like, for example, the extent of ciprofloxacin sensitivity of the *S. enterica* SR‐11 Δ*pasTI* mutant. These do not qualitatively affect the phenotypes or overall conclusions and are caused by the presence of plasmids (empty vector or complementation plasmid) in (b), while strains in (a) harbor no plasmid (see also Figure [A6c,d](#mbo31064-fig-0015){ref-type="fig"} for another phenotype affected by plasmid carriage). (d) The *pasTI* knockout did not affect the ciprofloxacin MIC of any strain except *E. coli* 55989 where it greatly reduced intrinsic ciprofloxacin resistance. It is therefore possible that for this strain (but not the others) at least part of the different survival between wild‐type and *pasTI* knockout can be explained by a difference in MIC. All data points in (a‐d) represent the mean of results from at least three independent experiments, and error bars indicate standard deviations. *ev* = empty vector](MBO3-9-e1064-g012){#mbo31064-fig-0012}

![In silico analysis of relationships between PasT/RatA and Coq10 homologs. (a) The illustration shows a protein sequence alignment of different PasT homologs (generated as described in Materials and Methods). For complementation experiments (e.g., in Figure [8](#mbo31064-fig-0008){ref-type="fig"}), we cloned the C‐terminus of Coq10A that is homologous to CC1736/PasT (highlighted by a red frame; the first and the last amino acids are indicated) without the N‐terminal mitochondrial targeting sequence. For completeness, a detailed amino acid sequence alignment of PasT~CFT073~ and Coq10*~S.cerevisiae~* is provided. (b) PasT structure prediction using Phyre2 (<https://www.sbg.bio.ic.ac.uk/phyre2>; Kelley et al., [2015](#mbo31064-bib-0037){ref-type="ref"}). The structure of *E. coli* CFT073 PasT was modeled with Phyre2 using the best‐matching template PDB entry 1t17 (CC1736 of *Caulobacter crescentus*---see also Figure [3](#mbo31064-fig-0003){ref-type="fig"} and (a)---and assigned a 100% confidence. The N‐terminus and C‐terminus are indicated by white letters. (c) Interaction partners of *E. coli* K‐12 MG1655 RatA (left) and *E. coli* CFT073 PasT (right) were analyzed using STRING ([https://string‐db.org/](https://string-db.org/); Szklarczyk et al., [2018](#mbo31064-bib-0072){ref-type="ref"}).](MBO3-9-e1064-g013){#mbo31064-fig-0013}

![Additional data related to gentamicin and zeocin MIC experiments. (a) Two additional independent replicates of the gentamicin MIC determination for *E. coli* CFT073 strains are shown that confirm the phenotype indicated in Figure [4c](#mbo31064-fig-0004){ref-type="fig"}, Figure [4d](#mbo31064-fig-0004){ref-type="fig"}, and Figure [8b](#mbo31064-fig-0008){ref-type="fig"}. (b, c) The experiments shown in Figure [4c](#mbo31064-fig-0004){ref-type="fig"}, Figure [4d](#mbo31064-fig-0004){ref-type="fig"}, Figure [8b](#mbo31064-fig-0008){ref-type="fig"}, and (a) were also performed with *E. coli* K‐12 MG1655 strains instead of *E. coli* CFT073 strains, revealing the same phenotypes of increased gentamicin/zeocin MIC in the absence of functional *ratA* without functional complementation by a homolog. For zeocin, data points represent the mean of results from three independent experiments, and error bars indicate standard deviations. (d, e) The MICs of *E. coli* O157:H7 EDL933, *E. coli* 55989, and *S. enterica* SR‐11 and their Δ*pasTI* derivatives for gentamicin (d) and zeocin (e) were determined by broth dilution assays. The bacteria carried either an empty vector (ev) or the complementation plasmid encoding *pasT*. We did not use the EDL933 strain in (e) because of problems with gentamicin resistance. Data points in (d) and (e) represent the mean of results from at least three independent experiments, and error bars indicate standard deviation.](MBO3-9-e1064-g014){#mbo31064-fig-0014}

![Additional data related to experiments assessing oxidative stress sensitivity. (a) *E. coli* O157:H7 EDL933, *E. coli* 55989, *S. enterica* SR‐11, and their Δ*pasTI* derivatives carrying either the empty vector (ev) or the complementation plasmid (p*pasT*) were spotted on LB agar plates to visualize differences in colony size. (b) Cultures of *E. coli* O157:H7 EDL933, *E. coli* 55989, *S. enterica* SR‐11, and their Δ*pasTI* derivatives were diluted and spotted on LB agar plates which we thereafter incubated in the absence of oxygen. [d]{.smallcaps}‐glucose (1% w/v) was added as a fermentable carbon source to LB agar plates incubated anaerobically. (c) Bacterial growth (colony‐forming units (cfu)/ml) and dynamics of cells surviving hydrogen peroxide (H~2~O~2~) treatment were determined for cultures of *E. coli* CFT073 wild‐type/Δ*pasTI* (left) and *E. coli* K‐12 MG1655 wild‐type/Δ*ratAB* (right) over time after inoculation from stationary phase into fresh medium (see Materials and Methods). In contrast to Figure [7a](#mbo31064-fig-0007){ref-type="fig"}, the bacteria do not carry the empty vector pNDM220 of the complementation constructs used in Figure [7c](#mbo31064-fig-0007){ref-type="fig"}, but this does not make a difference for *E. coli* CFT073 (compare the left panels to Figure [7a](#mbo31064-fig-0007){ref-type="fig"}). (d) The same experiment as described in Figure [7a](#mbo31064-fig-0007){ref-type="fig"} and (a) was performed with *E. coli* K‐12 MG1655 wild‐type/Δ*ratAB* carrying the pNDM220 plasmid. Note the difference in H~2~O~2~ sensitivity of the Δ*ratAB* mutant in panels (a) and (b) that precluded conclusive complementation experiments for this phenotype with *E. coli* K‐12 MG1655 strains. (e) The fraction of cells surviving hydrogen peroxide (H~2~O~2~) treatment 2 hr after inoculation was determined for cultures of *E. coli* K‐12 MG1655 Δ*ratAB* with and without pretreatment with the antioxidant vitamin C (ascorbate). All data points in (c‐e) represent the mean of results from at least three independent experiments, and error bars indicate standard deviations. (f) The colony sizes of *E. coli* K‐12 MG1655 strains harboring complementation plasmids encoding the *pasT* homolog *cc1736* from *C. crescentus* or human *coq10* under *Plac* control were analyzed on LB agar plates supplemented with 1% [d]{.smallcaps}‐glucose (repressing expression of complementation constructs) or 1 mM IPTG (inducing expression of complementation plasmids).](MBO3-9-e1064-g015){#mbo31064-fig-0015}

![The presence of *rpoS~am~* or *rpoS~wt~* alleles in *E. coli* CFT073 Δ*pasTI* does not affect any phenotype except the dynamics of H~2~O~2~ survival. (a) Bacterial growth (colony‐forming units (cfu)/ml) and dynamics of cells surviving hydrogen peroxide (H~2~O~2~) treatment were determined for cultures of *E. coli* CFT073 wild‐type/Δ*pasTI* with intact *rpoS* (middle panel) in comparison with the *E. coli* CFT073 strains with the *rpoS~am~* loss‐of‐function allele (left panel) and the *E. coli* K‐12 MG1655 strains (right panel). The left and right panels are copied from Figure [A6b](#mbo31064-fig-0015){ref-type="fig"} to enable a direct comparison. (b, c) The dynamics of ciprofloxacin tolerance throughout the growth phases of *E. coli* CFT073 and its Δ*pasTI* mutant were determined for a variant carrying an intact *rpoS* allele just like it had been done originally with the variant carrying inactive *rpoS* ~am~ (B; compare Figure [2a](#mbo31064-fig-0002){ref-type="fig"}). Time--kill curves of ciprofloxacin treatment 5 hr after inoculation (c) show biphasic killing kinetics, revealing that the difference in survival at this time point is due to different levels of persister cells. (d) The membrane potential of *E. coli* CFT073 *rpoS~wt~* and its Δ*pasTI* mutant was assessed using the fluorescent indicator dye DiOC2(3) just as shown for the *rpoSam* variants in Figure [4b](#mbo31064-fig-0004){ref-type="fig"}. All data points represent the mean of results from at least three independent experiments, and error bars indicate standard deviations. (e) Dynamics of colistin tolerance throughout the growth phases of *E. coli* CFT073, and its Δ*pasTI* mutant were determined for a variant carrying an intact *rpoS~wt~* allele as done originally for the variant carrying inactive *rpoS*am (Figure [A2b](#mbo31064-fig-0011){ref-type="fig"}).](MBO3-9-e1064-g016){#mbo31064-fig-0016}
